

Document D4

Opposition J. EP I 227 323
(Application No. EP02006640.3)
Uexküll & Stolberg
Beselerstr.4, 22607 Hamburg



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) Publication number : 0 450 931 A1

(12)

EUROPEAN PATENT APPLICATION

(21) Application number : 91302910.4

(51) Int. Cl.⁶ : G01N 33/576, C07K 15/00

(22) Date of filing : 03.04.91

(30) Priority : 04.04.90 US 504352

(72) Inventor : Houghton, Michael
53 Rosemead Court
Danville, California 94526 (US)
Inventor : Choo, Qu-Lim
5700 Fern Street
El Cerrito, California 94530 (US)
Inventor : Kuo, George
1370 Sixth Avenue
San Francisco, California 94112 (US)

(43) Date of publication of application :
09.10.91 Bulletin 91/41

(71) Representative : Goldin, Douglas Michael et al
J.A. KEMP & CO. 14, South Square Gray's Inn
London WC1R 5EU (GB)

(84) Designated Contracting States :
AT BE CH DE DK ES FR GB GR IT LI LU NL SE

(73) Applicant : CHIRON CORPORATION
4560 Horton Street
Emeryville California 94608 (US)

(54) Combinations of hepatitis C virus (HCV) antigens for use in immunoassays for anti-HCV antibodies.

(57) Combinations of HCV antigens that have a broader range of immunological reactivity than any single HCV antigen. The combinations consist of an antigen from the C domain of the HCV polyprotein, and at least one additional HCV antigen from either the NS3 domain, the NS4 domain, the S domain, or the NS5 domain, and are in the form of a fusion protein, a simple physical mixture, or the individual antigens commonly bound to a solid matrix.

Technical Field

The present invention is in the field of immunoassays for HCV (previously called Non-A, Non-B hepatitis virus). More particularly, it concerns combinations of HCV antigens that permit broad range immunoassays for anti-HCV antibodies.

Background

The disease known previously as Non-A, Non-B hepatitis (NANBH) was considered to be a transmissible disease or family of diseases that were believed to be viral-induced, and that were distinguishable from other forms of viral-associated liver diseases, including that caused by the known hepatitis viruses, i.e., hepatitis A virus (HAV), hepatitis B virus (HBV), and delta hepatitis virus (HDV), as well as the hepatitis induced by cytomegalovirus (CMV) or Epstein-Barr virus (EBV). NANBH was first identified in transfused individuals. Transmission from man to chimpanzee and serial passage in chimpanzees provided evidence that NANBH was due to a transmissible infectious agent or agents. Epidemiologic evidence suggested that there may be three types of NANBH: a water-borne epidemic type; a blood-borne or parenterally transmitted type; and a sporadically occurring (community acquired) type. However, until recently, no transmissible agent responsible for NANBH had been identified, and clinical diagnosis and identification of NANBH had been accomplished primarily by exclusion of other viral markers. Among the methods used to detect putative NANBH antigens and antibodies were agar-gel diffusion, counterimmunoelectrophoresis, immunofluorescence microscopy, immune electron microscopy, radioimmunoassay, and enzyme-linked immunosorbent assay. However, none of these assays proved to be sufficiently sensitive, specific, and reproducible to be used as a diagnostic test for NANBH.

In 1987, scientists at Chiron Corporation (the owner of the present application) identified the first nucleic acid definitively linked to blood-borne NANBH. See, e.g., EPO Pub. No. 318,216; Houghton et al., *Science* 244:359 (1989). These publications describe the cloning of an isolate from a new viral class, hepatitis C virus (HCV), the prototype isolate described therein being named "HCV1." HCV is a Flavi-like virus, with an RNA genome.

U.S. Patent Application Serial No. 456,637 (Houghton et al.), incorporated herein by reference, describes the preparation of various recombinant HCV polypeptides by expressing HCV cDNA and the screening of those polypeptides for immunological reactivity with sera from HCV patients. That limited screening showed that at least five of the polypeptides tested were very immunogenic; specifically, those identified as 5-1-1, C100, C33c, CA279a, and CA290a. Of these five polypeptides, 5-1-1 is located in the putative NS4 domain; C100 spans the putative NS3 and NS4 domains; C33c is located within the putative NS3 domain and CA279a and CA290a are located within the putative C domain. The screening also showed that no single polypeptide tested was immunologically reactive with all sera. Thus, improved tests, which react with all or more samples from HCV positive individuals, are desirable.

Disclosure of the Invention

Applicants have carried out additional serological studies on HCV antigens that confirm that no single HCV polypeptide identified to date is immunologically reactive with all sera. This lack of a single polypeptide that is universally reactive with all sera from individuals with HCV may be due, *inter alia*, to strain-to-strain variation in HCV epitopes, variability in the humoral response from individual-to-individual and/or variation in serology with the state of the disease.

These additional studies have also enabled applicants to identify combinations of HCV antigens that provide more efficient detection of HCV antibodies than any single HCV polypeptide.

Accordingly, one aspect of this invention is a combination of HCV antigens comprising:

- (a) a first HCV antigen from the C domain; and
- (b) at least one additional HCV antigen selected from the group consisting of
 - (i) an HCV antigen from the NS3 domain;
 - (ii) an HCV antigen from the NS4 domain;
 - (iii) an HCV antigen from the S domain; and
 - (iv) an HCV antigen from the NS5 domain.

In one embodiment, the combination of HCV antigens is in the form of a fusion protein comprised of the antigens. In an alternative embodiment, the combination of antigens is in the form of the individual antigens bound to a common solid matrix. In still another embodiment, the combination of antigens is in the form of a mixture of the individual antigens.

Another aspect of the invention is a method for detecting antibodies to HCV in a mammalian body compo-

5
uent suspected of containing said antibodies comprising contacting said body component with the above-described combination of HCV antigens under conditions that permit antibody-antigen reaction and detecting the presence of immune complexes of said antibodies and said antigens.

Another aspect of the invention is a method for detecting antibodies to HCV in a mammalian body component suspected of containing said antibodies comprising contacting said body component with a panel of HCV antigens, simultaneously or sequentially, comprising

- (a) a first HCV antigen from the C domain; and
- (b) at least one additional HCV antigen selected from the group consisting of
 - (i) an HCV antigen from the NS3 domain;
 - (ii) an HCV antigen from the NS4 domain;
 - (iii) an HCV antigen from the S domain; and
 - (iv) an HCV antigen from the NS5 domain under conditions that permit antibody-antigen reaction and detecting the presence of immune complexes of said antibodies and said antigens.

10
Another aspect of the invention is a kit for carrying out an assay for detecting antibodies to HCV in a mammalian body component suspected of containing said antibodies comprising in packaged combination

- (a) said combination of HCV antigens;
- (b) standard control reagents; and
- (c) instructions for carrying out the assay.

15
Brief Description of the Drawings

In the drawings:

Figure 1 is the nucleotide sequence of the cDNA sense and anti-sense strand for the HCV polyprotein and the amino acid sequence encoded by the sense strand.

20
Figure 2 is a schematic of the amino acid sequence of Figure 1 showing the putative domains of the HCV polypeptide.

Modes for Carrying Out the Invention

25
Definitions

"HCV antigen" intends a polypeptide of at least about 5 amino acids, more usually at least about 8 to 10 amino acids that defines an epitope found in an isolate of HCV. Preferably, the epitope is unique to HCV. When an antigen is designated by an alphanumeric code, the epitope is from the HCV domain specified by the alphanumeric.

30
"Synthetic" as used to characterize an HCV antigen intends that the HCV antigen has either been isolated from native sources or man-made such as by chemical or recombinant synthesis.

"Domains" intends those segments of the HCV polyprotein shown in Figure 2 which generally correspond to the putative structural and nonstructural proteins of HCV. Domain designations generally follow the convention used to name Flaviviral proteins. The locations of the domains shown in Figure 2 are only approximate. The designations "NS" denotes "nonstructural" domains, while "S" denotes the envelope domain, and "C" denotes the nucleocapsid or core domain.

40
"Fusion polypeptide" intends a polypeptide in which the HCV antigen(s) are part of a single continuous chain of amino acids, which chain does not occur in nature. The HCV antigens may be connected directly to each other by peptide bonds or be separated by intervening amino acid sequences. The fusion polypeptides may also contain amino acid sequences exogenous to HCV.

45
"Common solid matrix" intends a solid body to which the individual HCV antigens or the fusion polypeptide comprised of HCV antigens are bound covalently or by noncovalent means such as hydrophobic adsorption.

50
"Mammalian body component" intends a fluid or tissue of a mammalian individual (e.g., a human) that commonly contains antibodies produced by the individual. Such components are known in the art and include, without limitation, blood, plasma, serum, spinal fluid, lymph fluid, secretions of the respiratory, intestinal or genitourinary tracts, tears, saliva, milk, white blood cells, and myelomas.

"Immunologically reactive" means that the antigen in question will react specifically with anti-HCV antibody commonly present in a significant proportion of sera from individuals infected with HCV.

55
"Immune complex" intends the combination or aggregate formed when an antibody binds to an epitope on an antigen.

Combinations of HCV Antigens

Figure 2 shows the putative domains of the HCV polyprotein. The domains from which the antigens used in the combinations derive are: C, S (or E), NS3, NS4, and NS5. The C domain is believed to define the nucleocapsid protein of HCV. It extends from the N-terminal of the polyprotein to approximately amino acid 120 of Figure 1. The S domain is believed to define the virion envelope protein, and possibly the matrix (M) protein, and is believed to extend from approximately amino acid 120 to amino acid 400 of Figure 1. The NS3 domain extends from approximately amino acid 1050 to amino acid 1640 and is believed to constitute the viral protease. The NS4 domain extends from the terminus of NS3 to approximately amino acid 2000. The function of the NS4 protein is not known at this time. Finally, the NS5 domain extends from about amino acid 2000 to the end of the polyprotein and is believed to define the viral polymerase.

The sequence shown in Figure 1 is the sequence of the HCV1 isolate. It is expected that the sequences of other strains of the blood-borne HCV may differ from the sequence of Figure 1, particularly in the envelope (S) and nucleocapsid (C) domains. The use of HCV antigens having such differing sequences is intended to be within the scope of the present invention, provided, however, that the variation does not significantly degrade the immunological reactivity of the antigen to sera from persons infected with HCV.

In general, the HCV antigens will comprise entire or truncated domains, the domain fragments being readily screened for antigenicity by those skilled in the art. The individual HCV antigens used in the combination will preferably comprise the immunodominant portion (i.e., the portion primarily responsible for the immunological reactivity of the polypeptide) of the stated domain. In the case of the C domain it is preferred that the C domain antigen comprise a majority of the entire sequence of the domain. The antigen designated C22 (see Example 4, infra), is particularly preferred. The S domain antigen preferably includes the hydrophobic subdomain at the N-terminal end of the domain. This hydrophobic subdomain extends from approximately amino acid 199 to amino acid 328 of Figure 1. The HCV antigen designated S2 (see Example 3, infra), is particularly preferred. Sequence downstream of the hydrophobic subdomain may be included in the S domain antigen if desired.

A preferred NS3 domain antigen is the antigen designated C33c. That antigen includes amino acids 1192 to 1457 of Figure 1. A preferred NS4 antigen is C100 which comprises amino acids 1569 to 1931 of Figure 1. A preferred NS5 antigen comprises amino acids 2054 to 2464 of Figure 1.

The HCV antigen may be in the form of a polypeptide composed entirely of HCV amino acid sequence or it may contain sequence exogenous to HCV (i.e., it may be in the form of a fusion protein that includes exogenous sequence). In the case of recombinantly produced HCV antigen, producing the antigen as a fusion protein such as with SOD, alpha-factor or ubiquitin (see commonly owned U.S. Pat. No. 4,751,180, U.S. Pat. No. 4,870,008 and U.S. Pat. Application Serial No. 390,599, filed 7 August 1989, the disclosures of which are incorporated herein, which describe expression of SOD, alpha-factor and ubiquitin fusion proteins) may increase the level of expression and/or increase the water solubility of the antigen. Fusion proteins such as the alpha-factor and ubiquitin fusion are processed by the expression host to remove the heterologous sequence. Alpha-factor is a secretion system, however, while ubiquitin fusions remain in the cytoplasm.

Further, the combination of antigens may be produced as a fusion protein. For instance, a continuous fragment of DNA encoding C22 and C33c may be constructed, cloned into an expression vector and used to express a fusion protein of C22 and C33c. In a similar manner fusion proteins of C22 and C100; C22 and S2; C22 and an NS5 antigen; C22, C33c, and S2; C22, C100 and S2, and C22, C33c, C100, and S2 may be made. Alternative fragments from the exemplified domain may also be used.

Preparation of HCV Antigens

The HCV antigens of the invention are preferably produced recombinantly or by known solid phase chemical synthesis. They may, however, also be isolated from dissociated HCV or HCV particles using affinity chromatography techniques employing antibodies to the antigens.

When produced by recombinant techniques, standard procedures for constructing DNA encoding the antigen, cloning that DNA into expression vectors, transforming host cells such as bacteria, yeast, insect, or mammalian cells, and expressing such DNA to produce the antigen may be employed. As indicated previously, it may be desirable to express the antigen as a fusion protein to enhance expression, facilitate purification, or enhance solubility. Examples of specific procedures for producing representative HCV antigens are described in the Examples, infra, and in parent application Serial No. 456,637.

Formulation of Antigens for Use in Immunoassay

The HCV antigens may be combined by producing them in the form of a fusion protein composed of two

or more of the antigens, by immobilizing them individually on a common solid matrix, or by physically mixing them. Fusion proteins of the antigen may also be immobilized on (bound to) a solid matrix. Methods and means for covalently or noncovalently binding proteins to solid matrices are known in the art. The nature of the solid surface will vary depending upon the assay format. For assays carried out in microtiter wells, the solid surface will be the wall of the well or cup. For assays using beads, the solid surface will be the surface of the bead. In assays using a dipstick (i.e., a solid body made from a porous or fibrous material such as fabric or paper) the surface will be the surface of the material from which the dipstick is made. In agglutination assays the solid surface may be the surface of latex or gelatin particles. When individual antigens are bound to the matrix they may be distributed homogeneously on the surface or distributed thereon in a pattern, such as bands so that a pattern of antigen binding may be discerned.

Simple mixtures of the antigens comprise the antigens in any suitable solvent or dispersing medium.

Assay Formats Using Combinations of Antigens

The HCV antigens may be employed in virtually any assay format that employs a known antigen to detect antibodies. A common feature of all of these assays is that the antigen is contacted with the body component suspected of containing HCV antibodies under conditions that permit the antigen to bind to any such antibody present in the component. Such conditions will typically be physiologic temperature, pH and ionic strength using an excess of antigen. The incubation of the antigen with the specimen is followed by detection of immune complexes comprised of the antigen.

Design of the immunoassays is subject to a great deal of variation, and many formats are known in the art. Protocols may, for example, use solid supports, or immunoprecipitation. Most assays involve the use of labeled antibody or polypeptide; the labels may be, for example, enzymatic, fluorescent, chemiluminescent, radio-active, or dye molecules. Assays which amplify the signals from the immune complex are also known; examples of which are assays which utilize biotin and avidin, and enzyme-labeled and mediated immunoassays, such as ELISA assays.

The immunoassay may be, without limitation, in a heterogeneous or in a homogeneous format, and of a standard or competitive type. In a heterogeneous format, the polypeptide is typically bound to a solid matrix or support to facilitate separation of the sample from the polypeptide after incubation. Examples of solid supports that can be used are nitrocellulose (e.g., in membrane or microtiter well form), polyvinyl chloride (e.g., in sheets or microtiter wells), polystyrene latex (e.g., in beads or microtiter plates, polyvinylidene fluoride (known as Immulon™), diazotized paper, nylon membranes, activated beads, and Protein A beads. For example, Dynatech Immulon™ 1 or Immulon™ 2 microtiter plates or 0.25 inch polystyrene beads (Precision Plastic Ball) can be used in the heterogeneous format. The solid support containing the antigenic polypeptides is typically washed after separating it from the test sample, and prior to detection of bound antibodies. Both standard and competitive formats are known in the art.

In a homogeneous format, the test sample is incubated with the combination of antigens in solution. For example, it may be under conditions that will precipitate any antigen-antibody complexes which are formed. Both standard and competitive formats for these assays are known in the art.

In a standard format, the amount of HCV antibodies forming the antibody-antigen complex is directly monitored. This may be accomplished by determining whether labeled anti-xenogenic (e.g., anti-human) antibodies which recognize an epitope on anti-HCV antibodies will bind due to complex formation. In a competitive format, the amount of HCV antibodies in the sample is deduced by monitoring the competitive effect on the binding of a known amount of labeled antibody (or other competing ligand) in the complex.

Complexes formed comprising anti-HCV antibody (or, in the case of competitive assays, the amount of competing antibody) are detected by any of a number of known techniques, depending on the format. For example, unlabeled HCV antibodies in the complex may be detected using a conjugate of antixenogenic Ig complexed with a label, (e.g., an enzyme label).

In an immunoprecipitation or agglutination assay format the reaction between the HCV antigens and the antibody forms a network that precipitates from the solution or suspension and forms a visible layer or film of precipitate. If no anti-HCV antibody is present in the test specimen, no visible precipitate is formed.

The HCV antigens will typically be packaged in the form of a kit for use in these immunoassays. The kit will normally contain in separate containers the combination of antigens (either already bound to a solid matrix or separate with reagents for binding them to the matrix), control antibody formulations (positive and/or negative), labeled antibody when the assay format requires same and signal generating reagents (e.g., enzyme substrate) if the label does not generate a signal directly. Instructions (e.g., written, tape, VCR, CD-ROM, etc.) for carrying out the assay usually will be included in the kit.

The following examples are intended to illustrate the invention and are not intended to limit the invention

In any manner.

Example 1: Synthesis of HCV Antigen C33c

5 HCV antigen C33c contains a sequence from the NS3 domain. Specifically, it includes amino acids 1192-1457 of Figure 1. This antigen was produced in bacteria as a fusion protein with human superoxide dismutase (SOD) as follows. The vector pSODcf1 (Steiner et al. (1986), J. Virol. 58:9) was digested to completion with EcoRI and BamHI and the resulting EcoRI/BamHI fragment was ligated to the following linker to form pcf1EF:

10 GATC CTG GAA TTC TGA TAA
GAC CTT AAG ACT ATT TTA A

A cDNA clone encoding amino acids 1192-1457 and having EcoRI ends was inserted into pcf1EF to form 15 pcf1EF/C33c. This expression construct was transformed into D1210 *E. coli* cells.

The transformants were used to express a fusion protein comprised of SOD at the N-terminus and In-frame C33c HCV antigen at the C-terminus. Expression was accomplished by inoculating 1500 ml of Luria broth containing ampicillin (100 micrograms/ml) with 15 ml of an overnight culture of the transformants. The cells were grown to an O.D. of 0.3, IPTG was added to yield a final concentration of 2 mM, and growth continued until the 20 cells attained a density of 1 O.D., at which time they were harvested by centrifugation at 3,000 x g at 4°C for 20 minutes. The packed cells can be stored at -80°C for several months.

In order to purify the SOD-C33c polypeptide the bacterial cells in which the polypeptide was expressed 25 were subjected to osmotic shock and mechanical disruption, the insoluble fraction containing SOD-C33c was isolated and subjected to differential extraction with an alkaline-NaCl solution, and the fusion polypeptide in the extract purified by chromatography on columns of S-Sepharose and Q-Sepharose.

The crude extract resulting from osmotic shock and mechanical disruption was prepared by the following procedure. One gram of the packed cells were suspended in 10 ml of a solution containing 0.02 M Tris HCl, pH 7.5, 10 mM EDTA, 20% sucrose, and incubated for 10 minutes on ice. The cells were then pelleted by centrifugation at 4,000 x g for 15 min at 4°C. After the supernatant was removed, the cell pellets were resuspended 30 in 10 ml of Buffer A1 (0.01M Tris HCl, pH 7.5, 1 mM EDTA, 14 mM beta-mercaptoethanol [BME]), and incubated on ice for 10 minutes. The cells were again pelleted at 4,000 x g for 15 minutes at 4°C. After removal of the clear supernatant (periplasmic fraction I), the cell pellets were resuspended in Buffer A1, incubated on ice for 10 minutes, and again centrifuged at 4,000 x g for 15 minutes at 4°C. The clear supernatant (periplasmic fraction II) was removed, and the cell pellet resuspended in 5 ml of Buffer A2 (0.02 M Tris HCl, pH 7.5, 14 mM BME, 35 1 mM EDTA, 1 mM PMSF). In order to disrupt the cells, the suspension (5 ml) and 7.5 ml of Dyno-mill lead-free acid washed glass beads (0.10-0.15 mm diameter)(obtained from Glen-Mills, Inc.) were placed in a Falcon tube, and vortexed at top speed for two minutes, followed by cooling for at least 2 min on ice; the vortexing-cooling procedure was repeated another four times. After vortexing, the slurry was filtered through a scintered glass funnel using low suction; the glass beads were washed two times with Buffer A2, and the filtrate and washes 40 combined.

The insoluble fraction of the crude extract was collected by centrifugation at 20,000 x g for 15 min at 4°C, washed twice with 10 ml Buffer A2, and resuspended in 5 ml of MILLI-Q water.

A fraction containing SOD-C33c was isolated from the insoluble material by adding to the suspension NaOH (2 M) and NaCl (2 M) to yield a final concentration of 20 mM each, vortexing the mixture for 1 minute, centrifuging 45 it 20,000 x g for 20 min at 4°C, and retaining the supernatant.

In order to purify SOD-C33c on S-Sepharose, the supernatant fraction was adjusted to a final concentration of 6M urea, 0.05M Tris HCl, pH 7.5, 14 mM BME, 1 mM EDTA. This fraction was then applied to a column of S-Sepharose Fast Flow (1.5 x 10 cm) which had been equilibrated with Buffer B (0.05M Tris HCl, pH 7.5, 14 mM BME, 1 mM EDTA). After application, the column was washed with two column volumes of Buffer B. The 50 flow through and wash fractions were collected. The flow rate of application and wash, was 1 ml/min; and collected fractions were 1 ml. In order to identify fractions containing SOD-C33c, aliquots of the fractions were analyzed by electrophoresis on 10% polyacrylamide gels containing SDS followed by staining with Coomassie blue. The fractions are also analyzable by Western blots using an antibody directed against SOD. Fractions containing SOD-C33c were pooled.

55 Further purification of SOD-C33c was on a Q-Sepharose column (1.5 x 5 cm) which was equilibrated with Buffer B. The pooled fractions containing SOD-C33c obtained from chromatography on S-Sepharose was applied to the column. The column was then washed with Buffer B, and eluted with 60 ml of a gradient of 0.0 to 0.4 M NaCl in Buffer B. The flow rate for application, wash, and elution was 1 ml/min; collected fractions

were 1 ml. All fractions from the Q-Sepharose column were analyzed as described for the S-Sepharose column. The peak of SOD-C33c eluted from the column at about 0.2 M NaCl.

The SOD-C33c obtained from the Q-Sepharose column was greater than about 90% pure, as judged by analysis on the polyacrylamide SDS gels and immunoblot using a monoclonal antibody directed against human SOD.

Example 2: Synthesis of HCV Antigen C100

HCV antigen C100 contains sequences from the NS3 and NS4 domains. Specifically, it includes amino acids 1589-1931 of Figure 1. This antigen was produced in yeast. A cDNA fragment of a 1270 bp encoding the above amino acids and having EcoRI termini was prepared.

The construction of a yeast expression vector in which this fragment was fused directly to the S. cerevisiae ADH2/GAP promoter was accomplished by a protocol which included amplification of the C100 sequence using a PCR method, followed by ligation of the amplified sequence into a cloning vector. After cloning, the C100 sequence was excised, and with a sequence which contained the ADH2/GAP promoter, was ligated to a large fragment of a yeast vector to yield a yeast expression vector.

The PCR amplification of C100 was performed using as template the vector pS3-56C_{100m}, which had been linearized by digestion with SalI. pS3-56, which is a pBR322 derivative, contains an expression cassette which is comprised of the ADH2/GAPDH hybrid yeast promoter upstream of the human superoxide dismutase gene, and a downstream alpha factor transcription terminator.

The oligonucleotide primers used for the amplification were designed to facilitate cloning into the expression vector, and to introduce a translation termination codon. Specifically, novel 5'-HindIII and 3'-SalI sites were generated with the PCR oligonucleotides. The oligonucleotide containing the SalI site also encodes the double termination codons, TAA and TGA. The oligonucleotide containing the HindIII site also contains an untranslated leader sequence derived from the pgap63 gene, situated immediately upstream of the AUG codon. The pEco63GAPDH gene is described by Holland and Holland (1980) and by Kniskern et al. (1986). The PCR primer sequences used for the direct expression of C100m were:

5' GAG TGC TCA AGC TTC AAA ACA AAA TGG CTC
30 ACT TTC TAT CCC AGA CAA AGC AGA GT 3'

and

35 5' GAG TGC TCG TCG ACT CAT TAG GGG GAA
ACA TGG TTC CCC CGG GAG CCG AA 3'.

40 Amplification by PCR, utilizing the primers, and template, was with a Cetus-Perkin-Elmer PCR kit, and was performed according to the manufacturer's directions. The PCR conditions were 29 cycles of 94°C for a minute, 37°C for 2 minutes, 72°C for 3 minutes; and the final incubation was at 72°C for 10 minutes. The DNA can be stored at 4°C or -20°C overnight.

45 After amplification, the PCR products were digested with HindIII and SalI. The major product of 1.1 kb was purified by electrophoresis on a gel, and the eluted purified product was ligated with a large SalI-HindIII fragment of pBR322. In order to isolate correct recombinants, competent HB101 cells were transformed with the recombinant vectors, and after cloning, the desired recombinants were identified on the basis of the predicted size of HindIII-SalI fragments excised from the clones. One of the clones which contained the a HindIII-SalI fragment of the correct size was named pBR322/C100'd. Confirmation that this clone contained amplified C100 was by direct sequence analysis of the HindIII-SalI fragment.

50 The expression vector containing C100 was constructed by ligating the HindIII-SalI fragment from pBR322/C100'd to a 13.1 kb BamHI-SalI fragment of pBS24.1, and a 1369 bp BamHI-HindIII fragment containing the ADH2/GAP promoter. (The latter fragment is described in EPO 164,556). The pBS24.1 vector is described in commonly owned U.S.S.N. 382,805 filed 19 July 1989. The ADH2/GAP promoter fragment was obtained by digestion of the vector pPGAP/AG/HindIII with HindIII and BamHI, followed by purification of the 1369 bp fragment on a gel.

55 Competent HB101 cells were transformed with the recombinant vectors; and correct recombinants were identified by the generation of a 2464 bp fragment and a 13.1 kb fragment generated by BamHI and SalI diges-

tion of the cloned vectors. One of the cloned correct recombinant vectors was named pC100-d#3.

In order to express C100, competent cells of Saccharomyces cerevisiae strain AB122 (MATa leu2 ura3-53 prb 1-1122 pep4-3 prc1-407(cir-0)) were transformed with the expression vector pC100-d#3. The transformed cells were plated on URA-sorbitol, and individual transformants were then streaked on Leu⁻ plates.

Individual clones were cultured in Leu⁻, ura⁻ medium with 2% glucose at 30°C for 24-36 hours. One liter of Yeast Extract Peptone Medium (YEP) containing 2% glucose was inoculated with 10 ml of the overnight culture, and the resulting culture was grown at 30°C at an agitation rate of 400 rpm and an aeration rate of 1 L of air per 1 L of medium per minute (i.e., 1vvm) for 48 hours. The pH of the medium was not controlled. The culture was grown in a BioFlo II fermenter manufactured by New Brunswick Science Corp. Following fermentation, the cells were isolated and analyzed for C100 expression.

Analysis for expressed C100 polypeptide by the transformed cells was performed on total cell lysates and crude extracts prepared from single yeast colonies obtained from the Leu⁻ plates. The cell lysates and crude extracts were analyzed by electrophoresis on SDS polyacrylamide gels, and by Western blots. The Western blots were probed with rabbit polyclonal antibodies directed against the SOD-C100 polypeptide expressed in yeast. The expected size of the C100 polypeptide is 364 amino acids. By gel analysis the expressed polypeptide has a MW of 39.8K.

Both analytical methods demonstrated that the expressed C100 polypeptide was present in total cell lysates, but was absent from crude extracts. These results suggest that the expressed C100 polypeptide may be insoluble.

Example 3: Expression of HCV Antigen S2

HCV antigen S2 contains a sequence from the hydrophobic N-terminus of the S domain. It includes amino acids 199-328 of Figure 1.

The protocol for the construction of the expression vector encoding the S2 polypeptide and for its expression in yeast was analogous to that used for the expression of the C100 polypeptide, described in Example 2.

The template for the PCR reaction was the vector pBR322/P114a, which had been linearized by digestion with HindIII. P114a is a cDNA clone that encodes amino acids 199-328.

The oligonucleotides used as primers for the amplification by PCR of the S2 encoding sequence were the following.

For the 5'-region of the S2 sequence:

5' GAG TGC TCA AGC TTC AAA ACA AAA TGG GGC TCT
35 ACC ACG TCA CCA ATG ATT GCC CTA AC 3';

and

for the 3'-region of the S2 sequence:

5' GAG TGC TCG TCG ACT CAT TAA GGG GAC CAG TTC
ATC ATC ATA TCC CAT GCC AT 3'.

The primer for the 5'-region introduces a HindIII site and an ATG start codon into the amplified product. The primer for the 3'-region introduces translation stop codons and a SalI site into the amplified product.

The PCR conditions were 29 cycles of 94°C for a minute, 37°C for 2 minutes, 72°C for 3 minutes, and the final incubation was at 72°C for 10 minutes.

The main product of the PCR reaction was a 413 bp fragment, which was gel purified. The purified fragment was ligated to the large fragment obtained from pBR322 digested with HindIII and SalI fragment, yielding the plasmid pBR322/S2d.

Ligation of the 413 bp HindIII-SalI S2 fragment with the 1.36 kb BamHI-HindIII fragment containing the ADH2/GAP promoter, and with the large BamHI-SalI fragment of the yeast vector pBS24.1 yielded recombinant vectors, which were cloned. Correct recombinant vectors were identified by the presence of a 1.77 kb fragment after digestion with BamHI and SalI. An expression vector constructed from the amplified sequence, and containing the sequence encoding S2 fused directly to the ADH2/GAP promoter is identified as pS2d#9.

Example 4: Synthesis of HCV C Antigen

HCV antigen C22 is from the C domain. It comprises amino acids 1-122 of Figure 1.

- The protocol for the construction of the expression vector encoding the C polypeptide and for its expression
5 In yeast was analogous to that used for the expression of the C100 polypeptide, described supra, except for
the following.
The template for the PCR reaction was pBR322/ Ag30a which had been linearized with HindIII. Ag30 is a
cDNA clone that encodes amino acids 1-122. The oligonucleotides used as primers for the amplification by PCR
of the C encoding sequence were the following.

10

For the 5'-region of the C sequence:

5' GAG TGC AGC TTC AAA ACA AAA TGA GCA CGA
15 ATC CTA AAC CTC AAA AAA AAA AC 3',

and

20 for the 3'-region of the C sequence:

5' GAG TGC TCG TCG ACT CAT TAA CCC AAA TTG CGC
GAC CTA CGC CGG GGG TCT GT 3'.

- 25 The primer for the 5'-region introduces a HindIII site into the amplified product, and the primer for the 3'-region
introduces translation stop codons and a Sall site. The PCR was run for 29 cycles of 94°C for a minute, 37°C
for 2 minutes, 72°C for 3 minutes, and the final incubation was at 72°C for 10 minutes.

The major product of PCR amplification is a 381 bp polynucleotide. Ligation of this fragment with the Sa-
II-HindIII large Sall-HindIII fragment of pBR322 yielded the plasmid pBR322/C2.
30 Ligation of the 381 bp HindIII-Sall C coding fragment excised from pBR322/C2 with the 1.36 kb BamHI-
HindIII fragment containing the ADH2/GAP promoter, and with the large BamHI-Sall fragment of the yeast vec-
tor pBS24.1 yielded recombinant vectors, which were cloned. Correct recombinant vectors were identified by
the presence of a 1.74 kb fragment after digestion with BamHI and Sall. An expression vector constructed from
the amplified sequence, and containing the sequence encoding C fused directly to the ADH2/GAP promoter is
35 identified as pC22.

Analysis for expressed C polypeptide by the transformed cells was performed on total cell lysates and crude
extracts prepared from single yeast colonies obtained from the Leu⁻ plates. The cell lysates and crude extracts
were analyzed by electrophoresis on SDS polyacrylamide gels. The C polypeptide is expected to have 122
amino acids and by gel analysis the expressed polypeptide has a MW, of approximately 13.8 Kd.

40

Example 5: Synthesis of NS5 Polypeptide

This polypeptide contains sequence from the N-terminus of the NS5 domain. Specifically it includes amino
acids 2054 to 2484 of Figure 1. The protocol for the construction of the expression vector encoding the NS5
45 polypeptide and for its expression were analogous to that used for the expression of C33c (see Example 1).

Example 6: Radiolimmunoassay (RIA) for Antibodies to HCV

The HCV antigens of Examples 1-5 were tested in an RIA format for their ability to detect antibodies to
50 HCV in the serum of individuals clinically diagnosed as having HCV (Non-A, Non-B) and in serum from blood
given by paid blood donors.

The RIA was based upon the procedure of Tsu and Herzenberg (1980) in SELECTED METHODS IN CEL-
LULAR IMMUNOLOGY (W.H. Freeman & Co.), pp. 373-391. Generally, microtiter plates (Immulon 2,
65 Removewell strips) are coated with purified HCV antigen. The coated plates are incubated with the serum sam-
ples or appropriate controls. During incubation, antibody, if present, is immunologically bound to the solid phase
antigen. After removal of the unbound material and washing of the microtiter plates, complexes of human anti-
body-NANBV antigen are detected by incubation with ¹²⁵I-labeled sheep anti-human immunoglobulin. Unbound
labeled antibody is removed by aspiration, and the plates are washed. The radioactivity in individual wells is

EP 0 450 931 A1

determined; the amount of bound human anti-HCV antibody is proportional to the radioactivity in the well.

Specifically, one hundred microliter aliquots containing 0.1 to 0.5 micrograms of the HCV antigen in 0.125 M Na borate buffer, pH 8.3, 0.075 M NaCl (BBS) was added to each well of a microtiter plate (Dynatech Immulon 2 Removewell Strips). The plate was incubated at 4°C overnight in a humid chamber, after which, the antigen solution was removed and the wells washed 3 times with BBS containing 0.02% Triton X-100 (BBST). To prevent non-specific binding, the wells were coated with bovine serum albumin (BSA) by addition of 100 microliters of a 5 mg/ml solution of BSA in BBS followed by incubation at room temperature for 1 hour; after this incubation the BSA solution was removed. The antigens in the coated wells were reacted with serum by adding 100 microliters of serum samples diluted 1:100 in 0.01M Na phosphate buffer, pH 7.2, 0.15 M NaCl (PBS) containing 10 mg/ml BSA, and incubating the serum containing wells for 1 hr at 37°C. After incubation, the serum samples were removed by aspiration, and the wells were washed 5 times with BBST. Antibody bound to the antigen was determined by the binding of ¹²⁵I-labeled F'(ab)₂ sheep anti-human IgG to the coated wells. Aliquots of 100 microliters of the labeled probe (specific activity 5-20 microcuries/microgram) were added to each well, and the plates were incubated at 37°C for 1 hour, followed by removal of excess probe by aspiration, and 5 washes with BBST. The amount of radioactivity bound in each well was determined by counting in a counter which detects gamma radiation.

Table 1 below presents the results of the tests on the serum from individuals diagnosed as having HCV.

20

25

30

35

40

45

50

55

Table I

	<u>INDIVIDUAL</u>	<u>S2</u>	<u>C22</u>	<u>ANTIGEN</u>	<u>C100</u>	<u>C33c</u>	<u>NS5</u>
5	CVH IVDA	P	P		P(+++)	P	P
	CVH IVDA	P	P		P(+)	P	P
10	CVH IVDA	P	P		P(+)	P	P
	CVH NOS	P	P		P	P	P
	AVH NOS HS	N	N		N	N	N
	AVH NOS HS	P	N		N	N	N
15	AVH NOS HS	P	N		N	N	N
	AVH NOS HS	P/N	N		N	N	N
	AVH PTVH	N	N		N	P/N	N
20	AVH NOS HS	N	N		N	N	N
	AVH NOS	N	N		N	N	P
	AVH PTVH	N	N		N	N	N
	AVH IVDA	N	P		N	P	P
25	AVH PTVH	P	P/N		N	N	P
	AVH NOS	N	P		N	N	N
	AVH IVDA	N	P		N	P	P
	AVH NOS HS	P/N	N		N	N	N
30	AVH PTVH	N	N		N	N	P
	CVH IVDA	P	P		P	P	P
	CVH IVDA	P	P		P	P	P
35	AVH NOS HS	N	N		N	N	N
	CVH PTVH	P	P		N	N	N
	AVH PTVH	P	N		P(+)	P(+++)	N
	CVH PTVH	N	P		P	P	P
40	CVH NOS HS	P	P		P	P	N
	CVH NOS	N	P		P/N	P	P

	<u>INDIVIDUAL</u>	<u>S2</u>	<u>C22</u>	<u>C100</u>	<u>ANTIGEN</u>	
					<u>C33c</u>	<u>NS5</u>
5	CVH IVDA	N	N	N	P	N
	AVH IVDA	P	P	P	P	P
	AVH IVDA	P	P	P	P	P
	CVH IVDA	P	P	P	P	P
10	AVH IVDA	P/N	P	N	P	P
	AVH IVDA	N	P	P	P	N
	CVH PTVH	P	P/N	N	N	N
	CVH NOS	N	N	N	N	N
15	CVH NOS	N	N	N	N	N
	CVH IVDA	P	P	P	P	P
	AVH IVDA	P	P	P	P	P
20	CVH PTVH	P	P	P	P	P
	AVH PTVH?	N	P	P	P	P
	AVH IVDA	N	P	N	P	N
	AVH NOS	N	N	N	N	N
25	AVH NOS	N	N	N	N	N
	CVH NOS	N	P	N	N	P
	CVH NOS	P	P	N	N	N
	CVH NOS HS	P	P	P	P	P
30	CVH PTVH	P	P	N	P	P
	AVH nurse	P	P	N	N	N
	AVH IVDA	P	P	P	P	N
35	AVH IVDA	N	P	P(+)	P(++)	N
	AVH nurse	P/N	P	N	N	N
	AVH PTVH	P/N	P	P	N	P
	AVH NOS	N	P/N	N	N	P
40	AVH NOS	N	P	N	P	N
	AVH PTVH	P	P/N	N	N	N
	AVH PTVH	N	P	N	P	P
45	AVH PTVH	P	P	P	P	P
	AVH PTVH	N	P	N	N	P
	CVH PTVH	P/N	P	P(+)	P(++)	N
	AVH PTVH	N	P/N	P(+)	P(++)	P

50

55

	<u>INDIVIDUAL</u>				<u>ANTIGEN</u>	
		<u>S2</u>	<u>C22</u>	<u>C100</u>	<u>C33c</u>	<u> NSS</u>
	AVH PTVH	P	(?)	P	N	P
5	CVH PTVH	N	P	N	P	P
	CVH PTVH	N	P	P	P	P
	CVH PTVH	N	N	N	N	N
10	AVH NOS	N	N	N	N	N
	AVH nurse	P	P	N	N	N
	CVH PTVH	N	P	N	N	P
	AVH IVDA	N	P	N	P/N	N
15	CVH PTVH	P	P	P(+)	P(++)	P
	AVH NOS	P	P	N	N	N
	AVH NOS	P/N	P	N	N	P
	AVH PTVH	P/N	P	P	P	P
20	AVH NOS	N	P	P	P	P/N
	AVH IVDA	N	P	N	N	P
	AVH NOS	N	P/N	N	N	N
25	AVH NOS	P	P	N	N	P
	AVH PTVH	N	P	P	P	P
	crypto	P	P	P	P	P
	CVH NOS	N	P	P	P	P
30	CVH NOS	N	N	N	N	N
	AVH PTVH	N	P	P(+)	P(++)	N
	AVH PTVH	N	P/N	P(+)	P(++)	P
35	AVH PTVH	N	P/N	P(+)	P(++)	P
	CVH IVDA	P	P	P	P	P
	CVH IVDA	P	P	P	P	P
	CVH IVDA	P	P	P	P	P
40	CVH IVDA	P	P	P	P	P
	AVH NOS	N	P	N	N	N
	CVH IVDA	P	P	P	P	P/N
45	AVH IVDA	P	P	P	P	N
	AVH NOS	P	P	N	N	N
	AVH NOS	P	P	N	N	N
	CVH PTVH	P	P	N	N	P/N

	<u>INDIVIDUAL</u>	<u>S2</u>	<u>C22</u>	<u>C100</u>	<u>ANTIGEN</u>	
					<u>C33c</u>	<u>NS5</u>
5	AVH PTVH	N	P	N	P	P
	AVH NOS	N	N	N	N	N
	AVH NOS	N	P	N	N	N
	AVH NOS	P	N	N	N	N
10	CVH NOS	N	N	N	N	N
	AVH NOS	N	P/N	N	N	N
	AVH IVDA	N	P	P	P	P
	crypto	N	P	N	N	P/N
15	crypto	P	P	P/N	P	P
	AVH IVDA	N	N	P	P	N
	AVH IVDA	N	P	P	P	N
	AVH NOS	N	N	N	N	N
20	AVH NOS	N	N	N	N	N
	CVH IVDA	P	P	P	P	P
	CVH PTVH	N	N	N	N	N
25	CVH PTVH	P	P	P(+)	P(++)	P
	CVH PTVH	P	P	P(+)	P(++)	P
	CVH NOS	P/N	N	N	N	N
	CVH NOS	N	N	N	N	N
30	CVH PTVH	P	P	P	P	P
	CVH PTVH	P	P	P	P	P
	CVH PTVH	P	P	P	P	P
35	AVH IVDA	N	P	P	P	P
	CVH NOS	N	N	N	N	N
	CVH NOS	N	N	N	N	N
	CVH PTVH	P	P	P	P	P
40	AVH NOS	P	P	N	N	P/N
	AVH NOS	N	P/N	N	N	N
	CVH PTVH	P	P	N	N	P
45	CVH NOS	N	P/N	N	N	N
	AVH NOS	N	P	N	N	N
	AVH NOS	N	P	N	N	N
	CVH PTVH	N	P	N	N	N

50

55

	<u>INDIVIDUAL</u>				<u>ANTIGEN</u>	
		<u>S2</u>	<u>C22</u>	<u>C100</u>	<u>C33C</u>	<u>NS5</u>
5	AVH IVDA	N	P	N	P	P
	AVH NOS	P	N	N	N	N
	CVH NOS	N	N	N	N	N
	CVH NOS	N	N	N	N	N
10	CVH IVDA	P	P	P	P	P
	CVH IVDA	P/N	P	P	P	P
	CVH IVDA	P	P	P	P	P
	CVH IVDA	N	P	P	P	P
15	AVH NOS	N	P	N	N	N
	CVH IVDA	N	P	N	N	P
	CVH IVDA	N	P	N	N	P
20	AVH PTVH	P	P	N	P	P
	AVH PTVH	P	P	N	P	P
	CVH NOS	N	P/N	N	N	P/N
	CVH NOS	N	P	N	N	N
25	CVH NOS	N	N	N	N	N
	CVH PTVH	P	P	P	P	P
	CVH PTVH	P	P	P	P	P
	CVH PTVH	P	P	P	P	P
30	AVH IVDA	N	P	N	N	P
	AVH IVDA	N	P	P(++)	P(+)	P
	CVH PTVH	P	P	P	P	P
35	AVH PTVH	N	P	P	P	P
	CVH PTVH?	N	P	P	P	P
	CVH PTVH?	P/N	P	P	P	P
	CVH NOS HS	P	P	N	N	N
40	CVH IVDA	P	P	P	P	N
	CVH PTVH	N	P	P	P	P
	CVH PTVH	P	P	P	P	P/N
45	CVH NOS	P	P	P	P	P
	CVH IVDA	P	P	P	P	P
	CVH PTVH	P	P	P	P	N
	CVH PTVH	P	P	P	P	P

	<u>INDIVIDUAL</u>	<u>S2</u>	<u>C22</u>	<u>C100</u>	<u>C33c</u>	<u>ANTIGEN</u>
5	CVH NOS	N	N	N	N	P/N
	CVH NOS	N	P/N	N	N	P/N
	CVH PTVH	P	P	P	P	P
	CVH NOS	N	P	N	N	N
10	CVH NOS	N	N	N	N	N
	CVH NOS	P	P	N	N	P/N
	CVH NOS	N	N	N	N	N
	CVH NOS HS	P	P	P	P	P
15	CVH NOS HS	P	P	P	P	P
	CVH PTVH	N	N	N	N	N
	AVH PTVH	N	P	P	P	P
	AVH NOS			-	-	
20	CVH PTVH	N	P	P/N	P(++)	N
	crypto	P	P	P	P	P
	crypto	P	P	P	P	P
25	crypto	N	P	N	N	N
	crypto	N	P	P	P	P
	CVH PTVH	P	P	P	P	P
	crypto	N	N	N	N	N
30	crypto	N	P	N	N	P/N
	crypto	N	P	N	N	P
	crypto	P	P	P	P	P
35	crypto	N	P	N	P	N
	crypto			-	-	
	crypto			-	-	
	CVH NOS			-	-	
40	AVH-IVDA	N	P	N	P(+)	P

45

50

55

<u>INDIVIDUAL</u>	<u>S2</u>	<u>C22</u>	<u>C100</u>	<u>ANTIGEN</u>	<u>C33c</u>	<u>NS5</u>
AVH-IVDA	N	P/N	N		P(++)	N

- 5 AVH = acute viral hepatitis
 CVH = chronic viral hepatitis
 10 PTVH = post-transfusion viral hepatitis
 IVDA = intravenous drug abuser
 crypto = cryptogenic hepatitis
 NOS = non-obvious source
 15 P = positive
 N = negative

20 Per these results, no single antigen reacted with all sera. C22 and C33c were the most reactive and S2 reacted with some sera from some putative acute HCV cases with which no other antigen reacted. Based on these results, the combination of two antigens that would provide the greatest range of detection is C22 and C33c. If one wished to detect a maximum of acute infections, S2 would be included in the combination.

Table 2 below presents the results of the testing on the paid blood donors.

25 Table 2

	<u>Donor</u>	<u>Antigens</u>				
		<u>C100</u>	<u>C33c</u>	<u>C22</u>	<u>S2</u>	<u>NS5</u>
30	1	N	N	N	N	N
	2	N	N	N	N	N
	3	P	P	P	P	P
35	4	N	N	N	N	N
	5	N	N	N	N	N
	6	N	N	N	N	N
	7	N	N	N	N	N
40	8	N	N	N	N	N

45

60

65

EP 0 450 831 A1

	<u>Donor</u>	<u>Antigens</u>				
		<u>C100</u>	<u>C33c</u>	<u>C22</u>	<u>S2</u>	<u>NS5</u>
5	9	N	N	N	N	N
	10	N	N	N	N	N
	11	N	N	N	N	N
	12	N	N	N	N	N
10	13	N	N	N	N	N
	14	N	N	N	N	N
	15	N	N	N	N	N
	16	N	N	N	N	N
15	17	N	N	N	N	P
	18	P	P	P	P	P
	19	P	P	N	P	P
	20	P	P	N	P	P
20	21	N	N	N	N	P
	22	N	P	P	N	P
	23	P	P	P	P	P
	24	N	N	N	N	N
25	25	N	N	N	N	N
	26	N	N	N	N	N
	27	N	N	N	N	N
	28	N	N	N	N	N
30	29	N	N	N	N	N
	30	N	N	N	N	P
	31	P	P	P	N	N
	32	N	N	N	N	N
35	33	N	N	N	N	P
	34	N	N	N	N	P
	35	N	N	N	N	P
	36	N	N	N	N	N
40	37	N	N	N	N	N
	38	N	N	N	N	N
	39	N	N	N	N	N
	40	N	N	N	N	P
45	41	N	N	N	N	N
	42	N	N	N	N	N

		Antigens				
	Donor	C100	C33c	C22	S2	NS5
5	43	N	N	N	N	N
	44	N	N	N	N	N
	45	N	N	N	N	N
	46	N	N	N	N	N
10	47	P	P	N	N	P
	48	N	N	N	N	N
	49	N	N	N	N	N
	50	N	N	N	N	N
15	51	N	P	P	N	P
	52	N	N	N	N	N
	53	N	P	P	N	P
	54	P	P	P	P	N
20	55	N	N	N	N	N
	56	N	N	N	N	N
	57	N	N	N	N	N
	58	N	N	N	N	N
25	59	N	N	N	N	N
	60	N	N	N	N	N
	61	N	N	N	N	N
	62	N	N	N	N	N
30	63	N	N	N	N	N
	64	N	N	N	N	N
	65	N	N	N	N	N
	66	N	N	N	N	N
35	67	N	N	N	N	N
	68	N	N	N	N	N
	69	N	N	N	N	N
	70	P	P	P	P	P
40	71	N	N	N	N	N
	72	N	N	N	N	N
	73	P	P	P	P	N
	74	N	N	N	N	N
45	75	N	N	N	N	N
	76	N	N	N	N	P

		Antigens				
	Donor	C100	C33c	C22	S2	NS5
5	77	N	N	N	N	N
	78	N	N	N	N	N
	79	N	N	N	N	N
	80	N	N	N	N	N
	81	N	N	N	N	N
10	82	N	N	N	N	N
	83	P	P	P	N	N
	84	N	N	P	N	N
	85	N	N	N	N	N
	86	P	P	P	P	N
15	87	N	N	N	N	N
	88	N	N	N	N	N
	89	P	P	P	P	P
	90	P	P	P	P	N
	91	N	P	P	N	P
20	92	P	N	P	N	N
	93	N	N	N	N	N
	94	N	N	N	N	N
	95	N	N	N	N	N
	96	N	N	N	N	N
25	97	N	N	N	N	N
	98	N	P	P	P	P
	99	P	P	P	P	P
	100	N	N	N	N	N
	101	P	P	P	P	P
30	102	N	N	N	N	N
	103	N	N	N	N	N
	104					
	105					
	106	N	N	N	N	N
35	107	N	N	N	N	N
	108	N	N	P	N	P
	109	P	P	P	P	P
	110	P	P	P	N	P

		Antigens				
	<u>Donor</u>	<u>C100</u>	<u>C33c</u>	<u>C22</u>	<u>S2</u>	<u>NS5</u>
5	111	P	P	P	N	P
	112	N	N	N	N	N
	113	P	P	P	P	P
	114	N	N	N	N	N
10	115	N	N	N	N	N
	116	P	P	P	P	P
	117	N	N	N	N	N
	118	N	N	N	N	N
15	119	N	N	N	N	N
	120	P	P	P	P	P
	121	N	N	N	N	N
	122	N	P	P	N	P
20	123	N	N	N	N	N
	124	N	N	N	N	N
	125	N	N	N	N	N
	126	P	N	N	N	N
25	127	N	N	N	N	N
	128	N	N	N	N	N
	129	N	N	N	N	N
	130	P	P	P	P	N
30	131	N	N	N	N	P
	132	N	N	N	N	N
	133	N	N	N	N	N
	134	N	N	N	N	N
35	135	N	N	N	N	N
	136	N	N	N	N	N
	137	N	N	N	N	N
	138	N	N	N	N	N
40	139	N	N	N	N	N
	140	P	N	N	N	P
	141	P	N	P	P	P
	142	N	N	N	N	N
45	143	N	N	N	N	N
	144	N	N	N	N	N

EP 0450 931 A1

		Antigens				
	<u>Donor</u>	<u>C100</u>	<u>C33c</u>	<u>C22</u>	<u>S2</u>	<u>NS5</u>
5	145	N	N	N	N	N
	146	N	N	N	N	N
	147	N	N	N	N	N
	148	N	N	N	N	N
10	149	N	N	N	N	N
	150	N	N	N	N	N
	151	N	N	N	N	N
	152	N	N	N	N	N
15	153	N	N	N	N	N
	154	P	P	P	P	P
	155	N	N	N	N	N
	156	N	N	N	N	N
20	157	N	N	N	N	N
	158	N	N	N	N	N
	159	N	N	N	N	N
	160	N	N	N	N	N
25	161	P	P	P	P	P
	162	N	N	N	N	N
	163	N	N	N	N	N
	164	P	P	P	N	P
30	165	N	N	N	N	N
	166	P	P	P	N	P
	167	N	N	N	N	N
	168	N	N	N	N	N
35	169	N	N	N	N	N
	170	N	N	N	N	N
	171	N	N	N	N	N
	172	N	N	N	N	N
40	173	N	N	N	N	N
	174	N	N	N	N	N
	175	N	N	N	N	N
	176	N	N	N	N	N
45	177	N	N	N	N	P
	178	N	N	N	N	N

		Antigens				
	Donor	C100	C33c	C22	S2	NS5
5	179	N	N	N	N	N
	180	N	N	N	N	N
	181	N	N	N	N	N
	182	N	N	N	N	N
	183	P	P	P	P	P
10	184	N	N	N	N	N
	185	N	N	N	N	N
	186	N	N	N	N	N
	187	N	N	N	N	N
	188	N	P	P	N	N
15	189	N	N	N	N	N
	190	N	N	N	N	N
	191	N	N	N	N	N
	192	N	N	N	N	N
	193	N	N	N	N	N
20	194	N	N	N	N	N
	195	N	N	N	N	N
	196	N	N	N	N	N
	197	N	N	N	N	P
	198	P	P	P	N	N
25	199	N	N	N	N	P
	200	P	P	P	P	N

35 The results on the paid donors generally confirms the results from the sera of infected individuals.

Example 7: ELISA Determinations of HCV Antibodies Using Combination of HCV Antigens

40 Plates coated with a combination of C22 and C33c antigens are prepared as follows. A solution containing coating buffer (50mM Na Borate, pH 9.0), 21 ml/plate, BSA (25 micrograms/ml), C22 and C33c (2.50 micrograms/ml each) is prepared just prior to addition to the Removewell Immulon I plates (Dynatech Corp.). After mixing for 5 minutes, 0.2ml/well of the solution is added to the plates, they are covered and incubated for 2 hours at 37°C, after which the solution is removed by aspiration. The wells are washed once with 400 microliters wash buffer (100 mM sodium phosphate, pH 7.4, 140 mM sodium chloride, 0.1% (W/V) casein, 1% (W/V) Triton x-100, 0.01% (W/V) Thimerosal). After removal of the wash solution, 200 microliters/well of Postcoat solution (10 mM sodium phosphate, pH 7.2, 150 mM sodium chloride, 0.1% (w/v) casein, 3% sucrose and 2 mM phenylmethylsulfonylfluoride (PMSF)) is added, the plates are loosely covered to prevent evaporation, and are allowed to stand at room temperature for 30 minutes. The wells are then aspirated to remove the solution, and lyophilized dry overnight, without shelf heating. The prepared plates may be stored at 2-8°C in sealed aluminum pouches with desiccant (3 g Sorb-it™ packs).

In order to perform the ELISA determination, 20 microliters of serum sample or control sample is added to a well containing 200 microliters of sample diluent (100 mM sodium phosphate, pH 7.4, 500 mM sodium chloride, 1 mM EDTA, 0.1% (W/V) Casein, 0.01% (W/V) Thimerosal, 1% (W/V) Triton X-100, 100 micrograms/ml yeast extract). The plates are sealed, and are incubated at 37°C for two hours, after which the solution is removed by aspiration, and the wells are washed three times with 400 microliters of wash buffer (phosphate buffered saline (PBS) containing 0.05% Tween 20). The washed wells are treated with 200 microliters of mouse anti-human-IgG-horse radish peroxidase (HRP) conjugate contained in a solution of Ortho conjugate diluent

(10 mM sodium phosphate, pH 7.2, 150 mM sodium chloride, 50° (V/V) fetal bovine serum, 1% (V/V) heat treated horse serum, 1 mM K₃Fe(CN)₆, 0.05% (W/V) Tween 20, 0.02% (W/V) Thimerosal). Treatment is for 1 hour at 37°C, the solution is removed by aspiration, and the wells are washed three times with 400 ml wash buffer, which is also removed by aspiration. To determine the amount of bound enzyme conjugate, 200 microliters of substrate solution (10 mg O-phenylenediamine dihydrochloride per 5 ml of Developersolution) is added. Developer solution contains 50 mM sodium citrate adjusted to pH 5.1 with phosphoric acid, and 0.6 microliters/ml of 30% H₂O₂. The plates containing the substrate solution are incubated in the dark for 30 minutes at room temperature, the reactions are stopped by the addition of 50 microliters/ml 4N sulfuric acid, and the ODs determined.

In a similar manner, ELISAs using fusion proteins of C22 and C33c, and C22, C33c, and S2 and combinations of C22 and C100, C22 and S2, C22 and an NS5 antigen, C22, C33c, and S2, and C22, C100, and S2 may be carried out.

Modifications of the above-described modes for carrying out the invention that are obvious to those of skill in the fields of molecular biology, immunology, and related fields are intended to be within the scope of the following claims.

Claims

20. 1. A combination of synthetic hepatitis C viral (HCV) antigens comprising:
 - (a) a first HCV antigen from the C domain; and
 - (b) at least one additional HCV antigen selected from the group consisting of
 - (i) an HCV antigen from the NS3 domain;
 - (ii) an HCV antigen from the NS4 domain;
 - (iii) an HCV antigen from the S domain; and
 - (iv) an HCV antigen from the NS5 domain.
25. 2. A combination of synthetic hepatitis C viral (HCV) antigens comprising:
 - (a) a first HCV antigen consisting essentially of the C domain; and
 - (b) a second HCV antigen from the NS3 domain.
30. 3. The combination of claim 2 wherein the first HCV antigen is C22 and the second HCV antigen is C33c.
4. The combination of claim 2 including (c) a third HCV antigen from the S domain.
35. 5. The combination of claim 3 including (c) HCV antigen S2.
6. A combination of synthetic HCV antigens comprising:
 - (a) a first HCV antigen consisting essentially of the C domain; and
 - (b) a second HCV antigen from the NS4 domain.
40. 7. The combination of claim 6 wherein the first HCV antigen is C22 and the second HCV antigen is C100.
8. The combination of claim 6 including (c) a third HCV antigen from the S domain.
45. 9. The combination of claim 7 including (c) HCV antigen S2.
10. The combination of claim 1, 2, 3, 4, 5, 6, 7, 8 or 9 wherein the combination is in the form of a fusion polypeptide.
50. 11. The combination of claim 1, 2, 3, 4, 5, 6, 7, 8 or 9 wherein the combination is in the form of said first HCV antigen and said additional antigens individually bound to a common solid matrix.
12. The combination of claim 11 wherein the solid matrix is the surface of a microtiter plate well, a bead or a dipstick.
55. 13. The combination of claim 1, 2, 3, 4, 5, 6, 7, 8 or 9 wherein the combination is in the form of a mixture of said first HCV antigen and said additional HCV antigen(s).

14. A method for detecting antibodies to hepatitis C virus (HCV) in a mammalian body component suspected of containing said antibodies comprising contacting said body component with the combination of synthetic HCV antigens of claim 1, 2, 3, 4; 5, 6, 7, 8, 9, 10, 11, 12, or 13 under conditions that permit antibody-antigen reaction and detecting the presence of immune complexes of said antibodies and said antigens.
- 5 15. A method for detecting antibodies to hepatitis C virus (HCV) in a mammalian body component suspected of containing said antibodies comprising contacting said body component with a panel of synthetic HCV antigens comprising:
 - (a) a first HCV antigen from the C domain; and
 - 10 (b) at least one additional HCV antigen selected from the group consisting of
 - (i) an HCV antigen from the NS3 domain;
 - (ii) an HCV antigen from the NS4 domain;
 - (iii) an HCV antigen from the S domain; and
 - (iv) an HCV antigen from the NS5 domain under conditions that permit antibody-antigen reaction
 - 15 and detecting the presence of immune complexes of said antibodies and said antigens.
16. A kit for carrying out an assay for detecting antibodies to hepatitis C antigen (HCV) in a mammalian body component suspected of containing said antibodies comprising in packaged combination:
 - (a) the combination of synthetic HCV antigens of any one of claims 1-13;
 - 20 (b) standard control reagents; and
 - (c) instructions for carrying out the assay.

25

30

35

40

45

50

55

-341 GGCACCCCCCTGATGGGGGGGA
 CGGTGGGGGACTACCCCGGCT

-319 CACTCCACCAATGAATCACTTCCCTTGAGGAACCTACTGCTTCACGGCAGAAAGGGTCTAG
 STGAGGTGGTACTTAUTGAGGGGAACTCTTGTATGACAGAAGTGGCTTTCCAGATC

-259 CCATGGCGTTAGTATGAGTGTGCTSCAGCCTCCAGGACCCCCCTCCGGAGAGGCCATA
 CGTACCSAACATCACTCACAGCACCTCGAGGTCTTGGGGGAGGGCCCTCTGGTAT

-199 GTGGTGTGGGAACCGGTGAGTACACCCGAAATTGCGAGGACCGGGTCTTTTTCGA
 CACCAAGACCCCTGGCACTCATGTGGCCTAACGGTCCCTGGCCAGGAAAGAACCT

-139 TCAACCCGGTCAATGCCCTGGAGATTGGCGTGCCCCCGCAGACTGCTAGCCAGTACT
 AGTTGGGCGAGTTACGGACCTCTAACCGGACGGGGCGTCTIGACGGATCGGCTCATCA

-79 GTGGGGTGCAGAAAAGGCCCTGTGGTACTSCCTGATAGGGTGCTTGGAGTGCCTGGGAG
 CAACCCAGCCCCTGGCAACCATGACGGACTATCCACGAAACGGTCACTGGGCTCTC

-19 GTCTCGTAGACCGTGACCC
 CAGAGCATCTGGCACCTGG
 --- Arg Thr
 MetSerThrAsnPrLysProGlnLysLysAsnAsnThrAsnArgArgProGln
 ATGAGCACCGATCTAAACCTCAAAAACAAACGTAACCCAACCGTGGCCACAG
 TACTCTGCTTAGGATTGGAGTTTTTGTGATGTGGTGGCAAGGGGTGTC

61 AspValLysPheProGlyGlyGlyGlnIleValGlyGlyValTyrLeuLeuProArgArg
 GAGCTCAAGTCCCAGGTTGGGGTCAGATCGTTGGAGTTACTTGTGCGCCAGG
 CTGAGTCAAGGGCCCACGGCAGTCTACCAACCCCTCAAATGAAACCCGCGCTCC

121 GlyProArgLeuGlyvalAlaAlaThrArgLysSerGluArgSerGlnProArgGly
 GGCCTTAGATGGGTGGCGCGAGGAAAGACTCCGGAGGGTGGCAACTTGGAGGT
 CGGGGATCTAACCCACACCGGGCTGCTTCTGAAAGGCTGCGCACGGTNGAGCTCCA

181 ArgArgGlnProIlePrcLysAlaArgArgProGluGlyArgThrTrpAlaGlnProGly
 AGACGTCAGCCTATCCCCAAGGCCTCGGGCCGAGGACCTGGCTAGCCCCGG
 TCTGGCAGTCGGATAAGGGTCTCGAGCRGCGGGCTCCCTGGACCCGAGTGGGGG

241 TyrProTrpProLeuTyrGlyAsnGluGlyCysGlyTrpAlaGlyTrpLeuLeuSerPro
 TACCCCTGGGCCCCCTCTATGCCAAATGAGGGCTGGGGTGCGGGGAGTGGCTCCGGTCTCC
 ATGGGAAACCGGGACATACCGTTACTCCGAGCCCCACCCGCTACCGAGGGACAGAGGG

301 ArgGlySerArgProSerTrpGlyPrcThrAspProArgArgSerArgAsnLeuGly
 CGTGGCTTCGGCTCTAGCTGGGGCCCCACAGACCCGGCGIAGGTGGCTGGCAATTGGGT
 GCACCCAGGGCGATGACCTGGGTGTCGGGGGCGCATCCAGCSCGTTAAACCCA

361 LysValIleAspThrLeuThrCysGlyPheAlaAspLeuMetGlyTyrIleProLeuVal
 AACGTJATCGATACCTTACCTGCGGCTTCGGCACCTCATGGGTACATACCGCTGTC
 TTCCAJAGCTATGGGAATGACGGCGAGCGGGTGGAGTACCCCATGTATGGCGACCG

421 GlyAlaProLeuGlyGlyAlaAlaArgAlaLeuAlaHisGlyValArgValLeuAsp
 GGCCTCCCTGGAGGGCTGCGAGGGCCCTGGCCATGGGTGGGGTCTGGAAAGAC
 CGGGGGAGAGACCTCCGGCAGCGTCCGGGACCGCGTACCGCAGCCCCAAAGACCTCTG

Thr
481 GlyValAsnThrAlaThrGlyAsnLeuProGlyCysSerPheSerIlePheLeuAla
 GGCCTGAACATGCAACAGGGAACTTCTGSI TGCTTCTCTATCTTCCCTCTGGCC
 CGCACTTGTGACTCTGGCTTGGAGGACCAAGGACAAGAGATGAAACCAAGACCGG

541 LeuLeuSerCysIleThrValProAlaSerAlaTyrGlnValArgAsnSerThrGlyLeu
 CTGCTCTCTGCTGACTGTGCCGCTTGGCTTACCAAGTGCAACTCCAGGGGGCT
 GACGAGAGACGAACTGACACGGGCAAGCGTATGGTTCACGCGTTGAGCTGGGGGAA

601 TyrHisValThrAsnAspCysProAsnSerSerIleValTyrGluAlaAlaAspAlaIle
 TACCACTGTCACCAAGATTCCTAACTCGAATATGTCAGAGGGGGCCATGCCATC
 ATGGTGGACTGGTTACTAACGGGATTCAGCTATACACACAGCTCCGGGCTACGGTAC

Figure 1 (Sheet 1 of 10)

661 LeuHisThrProGlyCysValPheCysValArgGluGlyAsnAlaSerArgIysTrpVal
 CGCACACTCGGGGTGCGTCTTCGTTGAGGGCAACGCCCTCGAGGTTGGGTG
 GACGTTGAGGGCCACCGCAGGAACGACTTCCGTTGCGGAGCTCCACAACCCAC
 711 AlaMetThrProThrValAlaThrArgAspGly-LysLeuProAlaThrGlnLeuArgArg
 CGGATGACCCCCTACGGTGGCCACAGGGATGCGAACTCCCCCGACGCAGCTTCGACGT
 CGCTACTGGGGATGCCACCGGTGGTCCCTACCGTTGAGGGGGCTGCGTCAAGCTCCA
 781 HisIleAspLeuLeuValGlySerAlaThrLeuCysSerAlaLeuTyrValGlyAspLeu
 AACATCGATCTGCTTGCGGGAGCGCCACCCCTGTTGGGCCCCCTAACGTG3GGGACCTA
 GGTAGCTAGCGAACAGCCCTCGGTGGAGACAAGCCGGAGATGCCACCCCTGGAT
 841 CysGlySerValPhaLeuValGlyGlnLeuPheThrPheSerProArgArgHisTrpThr
 TCCGGGCTCTGCTCTCTGCGCCAACCTGTCACCTTCTCTCCCAGGGCCACCGGACG
 ACCTCCAGACAGAAGAACAGTGGTIGACAAGTGGAGAGAGGGTCCGGGCTGACCTGC
 901 ThrGlnGlyCysAsnCysSerIlePyrProGLy-HisIleThrGlyHisArgMetAlaTrp
 ACCCAAGGTGCAATTGCTCTACATCCGGCATATAACGGTCACCCATGGCATGG
 TGCGTTCCAACGTTAACGGAGATAAGGGCCGATATGGCCAGTGGCGTACCGTACC
 Val
 961 AspMetMetMetAsnTrpSerProThrThrAlaLeuValMetAlaGlnLeuLeuArgIle
 CATATCATGATGAACTGGTCCCCTACGACGGCGTGGTAAATGGCTCAGCTGCTCCGGATC
 CTATACTACTTGACCAGGGATGCTGCCGAACCATACCGAGTCGACGAGGGCTAG
 1021 ProGlnAlaIleLeuAspMetIleAlaGlyAlaLysTrpGlyValLeuAlaGlyIleAla
 CCACAAAGCCATCTGGACATGATCGCTGGTGTCACTGGGGAGTCCCTGGGGGGCATACGG
 GTGTTGGTAGAACCTGACTAGGACCAACGGATGACCCCTCAGGACCCGGTATCGC
 1081 TyrPheSerMetValGlyAsnTrpAlaLysValLeuValLeuLeuLeuPheAlaGly
 TATTTCTOCATGGTGGGAACTGGCGAAGGCTCTGGTAGTGCTGCTGCTATTGGCCGG
 ATAAAGGGTACACCCCTGACCCCTTCCXGGACCATCAGCACGACGATAAACGGCC
 1141 ValAspAlaGluThrHisValThrGlyGlySerAlaGlyHisThrValSerGlyPheVal
 GTGGACCGGAAACCCACGTCACCGGGGAAGTGCGGCCACACTGTGCTGGATTGTT
 CAGCCTGGCTTGGTGCAGTGGCCCTTCAGGGGGTGACACAGACCTAAACAA
 1201 SerLeuLeuAlaProGlyAlaLysGlnAsnValGlnLeuIleAsnThrAsnGlySerTrp
 AGCCTCCCTGCAACCCAGGGCAAGCAGTCAGCTGATCACACCAACGGCAGTTGG
 TCGGAGGAGCGTGGTCCGGTTCGCTTGAGGTCGACTAGTTGGTGGTCCGTCACC
 1261 HisLeuAsnSerThrAlaLeuAsnCysAsnAspSerLeuAsnThrGlyTrpLeuAlaGly
 CACCTCAATAGCACGGCCCTGACCTGCAATGATAGCCAAACACGGCTGGTGGCAGGG
 GTGGACTTATCGTGGCCGGACTGACGTTACTATGGAGTTGGCCGACCAACGGTCCC
 1321 LeuPheTyrHisHisLysPheAsnSerSerGlyCysProGluArgLeuAlaSerCysArg
 CTTTCTATCACCAAGTCACACTCTCAGGCTGCTCTGAGAGGCTAGCCAGCTGCCA
 GAAAAGATAGTTGGTGTCAAGTGGAGTCCGACAGGACTCTCGATCGTCAGGGCI
 1381 ProLeuThrAspPheAspGlnGlyTrpGlyProIleSerTyrAlaAsnGlySerGlyPro
 CCCCTTACCGATTTGACCGGCTGGGCCATACGTTATGCAAACGGCAAGCGGGCCC
 GGGGATGGCTAAACTGGTCCGACCCGGATAGTCATAACGGTGGCCTTCGCGGGGG
 1441 AspGlnArgProTyrCysTrpHisTyr-ProProLysProCysGlyIleValProAlaLys
 GACCAAGCGCCCTACTGCTGGCACTACCCGCCAAACCTTGCGTATTTGGCCCGAAG
 CTGGTCGGGGATGACGACGGTGAATGGGGGTTTGGAAACCCATAACCGGCGCTTC
 1501 SerValCysGlyProValTyrTysPheThrProSerProValValValGly-ThrThrAsp
 AGTGCTGTTGCTGGTATATGCTCACTTCACGCCCCCTGGTGGGGAAACGACCGAC
 TCACACACACCCAGGCCATATAACGAAGTGAGGGTGGGGGACCCACCAACCTGCTGGCT
 1561 ArgSerGlyAlaProThrTyrSerTrpGlyGluAsnAspThrAspValPheValLeuAsn
 AGGTGGCGCCGCCACCTACAGCTGGGTSAAAATGATACGGACGTTCGTCCTAAC
 TOCAGCCCGCGCGGGTGGATGCGACCCCTTAACTGAGGCTGAGGAAACGGAAATG
 AsnThrArgProProLeuGlyAsnTrpPheGlyCysThrTrpMetAsnSerThrGlyPhe

Figure 1 (Sheet 2 of 10)

-t 2- :ATRCCAGGCCACCGCTGGGCAATTGGTTGGTACCTGGATGAACTCACGGATC
 TTAGGTTGGTGGAACCGTAAACCAAGCCAAACACCCCTGCAC

1681 ThrLysValCysGlyAlaProProCysValIleGlyGlyAlaGlyAsnAsnThrLeuHis
 ACCAAAGTGCGGGAGCGCTCTCTGGTGTATCGGAGGGCGGGCAACACACCCCTGCAC
 TGGTTTACACGCCCTCGGGAGGAAACAGTACCCCTCCCCGCCGTGTGTTGGGAGCTG

1741 CysProThrAspCysPheArgLysHisProAspAlaThrTyrSerArgCysGlySerGly
 TGCCCCTACTGATGCTTCGCAAGCATCGGAGCCACATACTCTGGTGCCTCTCCGGT
 ACAGGGCTAAGGAAGGCTTCGTAGGCCCTGGGGTGTATGAGAGGCCACGCCAGGGCA

Ile
 1801 ProTrpLeuThrProArgCysLeuValAspTyrProTyrArcLeuTrpHisTyrProCys
 CCTCTGGATCACACCCAGGTGCCCTGGCAACTAACCGCTATAGGCTTGGCAATTATCTCTG
 GGGACCTAGTGTGGGTCACGGACCAGCTGATGGGAAATACCGAAACCGTAATAGGAACA

1861 ThrIleAsnTyrThrIlePheLysIleArgMetTyrValGlyGlyValGlyHisArgLeu
 ACCATCAACTACACCATATTAAATCAGGATGTAAGTGGGAGGGCTGAACACAGGCTG
 TGGTATGATGTGGTATAAATTAGTGCCTACAGCACCCCTCCCCAGCTGTGTCAGCAG

1921 GluAlaAlaCysAsnTrpThrArgGlyGluArgCysAspLeuGluAspArgAspArgSer
 GAAGCTGCCCTGCAACTGGACGCCGGCGAACGTTGGAGATCTGGAGACACGGACAGGTC
 CTTCGACGGACGGTACCTGGGCCCCCTGGCAACGCTAGACCTTGTGCTCTGTCCAGG

1981 GluLeuSerProLeuLeuLeuThrThrThrGlnTrpGlnValLeuProCysSerPheThr
 GAGCTCAGGCCGTTACTGCTGACCAACTACACAGTGGCAGGTCTCCCGTGTCTTCACA
 CTCTGAGTGGGCAATGACGATGGTATGTCACCGTCCAGGAGGGCACAGGAAGTGT

2041 ThrLeuProAlaLeuSerThrGlyLeuIleHisLeuHisGlnAsnIleValAspValGln
 ACCCTTACCAAGCCTTGCCACCGCCTCATCCACCTCACCAGAACATTGGGACCTGGCAG
 TGGGATGGTGGAACAGGTGGCCGACTAGGTGGAGGTGGTGTAAACACCTGCACTGCA

2101 TyrLeuTyrGlyValGlySerSerIleAlaSerTrpAlaIleLysTrpGlyTyrValVal
 DACTTGTAACGGGGTGGGGTCAGCATCGCCTGGCCATTAAAGTGGGATACGTCCT
 ATGNAATGCCCCACCCCAAGGTTCGTAGCGCAGGACCCGTAATTACCCCTATGCAAGCA

2161 LeuLeuPheLeuLeuLeuAlaAspAlaArgValCysSerCysLeuTrpMetMetLeuLeu
 CTCTCTTCTCTCTGCTGAGACGCCGGCTGCTCTGCTTGTGGATGATGCTACTC
 GAGGACAAAGAACGCAACGGTCTGCGCGCAGACGAGGAGCAACACCTACTACGATGAG

2221 IleSerGlnAlaGluAlaAlaLeuGluAsnLeuValIleLeuAsnAlaAlaSerLeuAla
 ATATCCCCAACGGGAGGGCCGCTTGGAGAACCTCGTAATACTCTAAATGAGCATCCCTGGCC
 TATAGGGTTCGCCCTCCGGCAAACCTCTTGGAGCATTAATGAAATTACGTCAGGGACCGG

2281 GlyThrHisGlyLeuValSerPheLeuValPhePheCysPheAlaTrpTyrLeuLysGly
 CGGACCGACGGCTGTATCTCTCTGCTGTTCTGCTTGGCATGGTATTGGAAAGGGT
 CCTCTGGTGGCAAGAACATAGGAAGGAGCACLAGAGAACGCAACGTAACCTTCCCA

2341 LysTrpValProGlyAlaValTyrThrPheTyrGlyMetTrpProLeuLeuLeuLeu
 KAGTGGGIGCCCCAGCGGGCTACACCTTCTACGGGATGTGGCCTCTCTGCTGCTGCT
 TTACCCACGGGCTCGCCAGAATGTTGGAGATGCCCTACACGGAGAGGGAGGACGAGGAC

2401 LeuAlaLeuProGlnArgAlaTyrAlaLeuAspThrGluValAlaAlaSerCysGlyGly
 TTGGCTTGGCCCAAGCGGGCTACGCCCTGACACCGAGGTGGCCCGCTGIGTGGGGGT
 AACCCCAACGGGCTCCCCCGCAAGCTGCGCAGCTGCTCCACCGGCCAGCACACCGCA

2461 ValValLeuValGlyLeuMetAlaLeuSerProTyrTyrLysArgTyrIleSer
 STGTTCTGCTGGGCTACTCTGCACTATACAAAGCGCTATATCAGC
 CAACAAGAGCAGCCAACTACCGCAGCTGAGACAGTGGTATAATGTTGGGATATAGTCG

(Asn)
 2521 TrpCysLeuTrpTrpLeuGlnTyrPheLeuThrArgValGluAlaGlnLeuHisValTrp
 TGGTGGCTTGTGGTGGCTCAGTATTTCTGACCAAGAGTGGAAAGCGCAACTCCACGTCGG
 ACCACGAAACCCACCGAAGTCATAAAAGACTGGTCTCACCTICGGTGTGACGCTG
 ACC

IleProProLeuAsnValArgGlyGlyArgAspAlaValIleLeuLeuMetCysAlaVal

Figure 1 (Sheet 3 of 10)

Figure 1 (Sheet 4 of 10)

3601 TCCCGGCCACACGTGGCACCTCACCGATTCCACCTGAAATAGGGACACCTCTTG
 LeuGluThrThrMetArgSerProValPheThrAspAsnSerSerProProValValPro
 TTAGA2ACAACCATGAGGTCCCCSGTGTCAACGGATAACTCTCTCACCAAGTAGTGCCC
 GAICCTTGTGCGTACTCCAGGGGCCACAAGTGCCTATTCAGGAGAGGTGGTCATCACGGG
 3661 GluSerPheGlnValAlaHisLeuHisAlaFroThrGlySerGlyLysSer-ThrLysVal
 CAGAGTTCCAGGTGGCTACCTCCAGCTCCCCAACAGCAGCGCAAAGCACCAAGGTC
 GTCTCGAAGGTCCACCGAGTGGAGGIACGAGGGTGTCCGTCGCGGTTTGTGGTTCCAG
 3721 ProAlaAlaTyrAlaAlaGlnSlyTyrLysValLeuValLeuAsnProSerValAlaAla
 CGGGCTGCTATGCAAGCTCAGGGCTATAAGGTGTAGTACTCAACCCCTCTGTGCTGCA
 GCGCGACGTATACTGTCGAGTCCCATAITCCACCGATCATGAGTTGGGAGACACCGACGT
 Leu
 3781 ThrLeuGlyPheGlyAlaTyrMetSerLysAlaHisGlyIleAspProAsnIleArgThr
 AACATGGCTTGGTGTCTACATCTCCAAGGCTCAAGGGATCGATCTIAACATCAGGACC
 TCTGACCCGAAACCCAGGAATGTACAGGTTCGAGTACCCAGCTAGTAGGATTGTAGTCCTGG
 3841 GlyValArgThrIleThrThrGlySerProIleThrTyrSerThrTyrGlyLysPhaLeu
 GGGGTGAGAACAAATTACCAACTGGCAGCCCCATCACCTACTCCACCTACGGCAAGTTCCTT
 CCCACTCTCTGTTAATGGTGCACCTCGGGTAGTGCATGAGGTGGATGCCGTTCAAGGAA
 3901 AlaAspGlyGlyCysSerGlyGlyAlaTyrAspIleIleCysAspGluCysHisSer
 GCGCACGGGGGGTGCCTGGGGGGCTTEATGACATAATAATTGTGACGAGTGCCACTCC
 CGGCTSCGGCCACGAGCCCCCSCGAATACTGTATTAAACACTGCTCACGGTGAGG
 (Val)
 3961 ThrAspAlaThrSerIleLeuGlyThrValLeuAspGlnAlaGluThrAlaGly
 ACCGATGCCACATCCATCTGGGCACTGGCACTGTCTTGACCAAGCAGAGACTGGGGGG
 TGCCIAACCGTGTAGGTAACCCGTAGCCGTACAGAACTCCCTGCTCTGACCCCCC
 4021 AlaArgLeuValValLeuAlaIleGlyThrProProGlySerValThrValProHisPro
 GCGAGACTGGTGTGCTGGCCACCCCCCTGGGCTGGTCACTGTGCCCCATCCC
 CGCTTGACCAACAGCAGGGTGGGGAGGCGAGGAGTGCACCGGGTAGGG
 4081 AspIleGluGluValAlaLeuSerThrThrGlyIleAspProPheTyrGlyLysAlaIle
 AACATCGAGGTGTGCTCTGTCACCCACCGGAGAGATCCCTTTACGGCAAGGCTATC
 TGTAGCTCTCCACGACAGGTGGTGGCTCTAGGGAAAATGCCGTTCCGATAG
 4141 ProLeuGluValIleLysGlyArgHisSerLysSerLysCys
 CCCCTCGAAGTAACTCAGGGGGGAGACATCTCATCTCTGTCATTCAAGAAGAAGTGC
 GGGGAGCTCTTACGAGGTGGTGGCTCTAGGGAAAATGCCGTTCCGATAG
 4201 AspGluLeuAlaAlaLysLeuValAlaLeuGlyIleAsnAlaValAlaTyrTyrArgGly
 GAGGAACCTGGCGCAAGCTGGTCGCACTGGCATTCAATCCCCTGGCTACTACCGCGGT
 CTGCTTGACGGGCTTTCGACCGGTAACCGTAGTACGGCACCGGATATGGCGCCA
 4261 LeuAspValSerValIleProThrSerGlyAspValValValAlaThrAspAlaLeu
 CTGACGGTGTCCGTATCCGACCAAGGGCGAATGTTGCTGCTCTGGCAACCGATCCCCTC
 GAACTGCAAGGCACTAGGGCTGGTCSCCGCTACAAACAGCAGCACCGTTGGCTACGGGAG
 TYR
 4321 MetThrGlyTyrThrGlyAspPheAspSerValIleAspCysAsnThrCysValThrGln
 ATGACCCGGCTATCCGGCGACTCTGACTCGGTGATAGACTGCAATACTGAGTGTGTCACCCAG
 TACTGGCCGATATGCCGCTGAAGCTGAGCAACTATCTGACCTATGCAACAGTGGTC
 (Ser)
 4381 ThrValAspPheSerLeuAspProPheThrPheThrIleGluThrIleThrLeuProGlnAsp
 AACACTCGATTTCAGGCTTGACCCACCTTACCAATTGAGACAACTACGCTCCCCAGGAT
 TGTAGCTAAAGTCGGAACTGGCACTGGAGTGGAGTGTAACTCTGTTAGTGCAGGGGGTCTA
 4441 AlavaSerArgThrGlnArgArgGlyArgThrGlyArgGlyLysProGlyIleTyrArg
 GCCTGCTCCCGCACTCAACGTCGGGGCAGGACTGGCAGGGGAAGCCAGGCTTACAGA
 CGACAGGGCGTGAGTTGCAAGCCCCCTGACCGTCCCCCTGGTCCGTAGAATCT

Figure 1 (Sheet 5 of 10)

4501 PheValAlaProGlyGluArgProSerGlyMetPheAspSerSerValLeuCysGluCys
 TTAGTGGCACCGGGGGAGCGCCCTCCGGCATGTCGATCGTCGTCCTCTGAGAGTC
 AACACCGTGCCCCCTCGCGGSGAGGCGTACAAGCTGAGCAGGCAGGAGAACACTCAGC

 4551 TyrAspAlaGlyCysAlaTrpTyrGluLeuThrProAlaGluThrThrValAlaLeuArg
 TAGAAGCAGGCTGTGCTTGGTATGAGCTAACCCCCGGAGACTACAGTTAGGCTACGA
 ATACTCGTCCGACACGARCCATCTCCAGTGGGGCGGCTCTGATGTCATACTCGATGCT

 4601 AlaTyrMetAsnThrProGlyLeuPheValCysGlnAspHisLeuGluPheTrpGluGly
 GCGTACAGAAGAACCCCCGGGCTTCCGIGIGCCAGGACCATCTGAATTGGGAGGGC
 CGCATGTACTTGTTGGGGCCCCGAGGGCACACGGCTCTGGTAGAACTTAAACCTCCCG

 4651 ValPheThrGlyLeuThrHisIleAspAlaHisPheLeuSerGlnThrLysGlnSerGly
 GTCTTACAGGCCCACTCATATAAGATGCCACTTCTATCCCAGACRAAGCRGAGTGGG
 CAGAAATGTCGGAGTGAGTATACTACGGGTAAGAGATAGGGCTGTITCGCTCACCC

 4701 GluAsnLeuPheTyrLeuValAlaTyrGlnAlaThrValCysAlaArgAlaGlnAlaPro
 GAGAACCTTCTTACCTGGTAGCGTACCAAGCACCCTGAGCTAGGGCTCAAGCCCT
 CTCTTGGAGGAATGGACCATCGCAAGGTTGGTGGCACACGGGATCCGAATTGGGAG

 4751 ProProSerTrpAspGlnMetTrpLysCysLeuIleArgLeuLysProThrLeuHisGly
 CCCCCATCGGGGACAGATGGAAAGTGTGTTGATTCGCTCAAGCCCACCCCTCCATGGG
 GGGGGTAGCACCTGGTCTACACCTCACAAACTAACGGGAGTTGGGTGGAGGTACCC

 4801 ProThrProLeuLeuTyrArgLeuGlyAlaValGlnAsnGluIleThrLeuThrHisPro
 CCAACACCCCTGCTATACAGACTGGCGCTGTCAAGAATGAAATCACCTGACGCCACCCA
 GTTGTGGGAGCAGATATGTCGACCCGGCACAGTCTACTTTAGTGGACTGCGTGGGT

 4851 ValThrLysTyrIleMetThrCysMetSerAlaAspLeuGluValValThrSerThrTrp
 GTCACCTAAATACATCATGACATGCAATGTCGGCGACCTGGAGGTCGTACCGAGCACCTGG
 CAGTGTTTATGAGTACTGTACGTCAGCCGGCTGGACCTCAGCAGTGTGGACCC

 4901 ValIleValGlyGlyValLeuAlaAlaLeuAlaAlaTyrCysLeuSerThrGlyCysVal
 GTGCTTGGGGGGCTCTGGCTTGGCTGGCGTATGGCTGTCAACAGGCGAGCGT
 CACGAJCAACCCGGGAGGACTGACGAAACCGGCGATAACGGACAGTGTCCGACGCAC

 4951 ValIleValGlyArgValValLeuSerGlyLysProAlaIleIleProAspArgGluVal
 GTCATAGTGGCAGGGCTGTCCTGTCGGGAACGCCGGAAATCATACCTGACAGGGAGTC
 CAGTATCACCCGCTCCAGCAGAAACAGGCCCTCGGGCTTGTATGGACTGTCCTCAG

 5001 LeuTyrArgCysPheAspGluMetGluGluCysSerGlnHisLeuProTyrIleGluGln
 CCTCTACGAGAGCTGATGAGATGGAAGAGTCTCTCAGACTAACCTGACATCGAGCAA
 GAGTGGCTCTCAAGCTACTCTACCTCTCACGAGACTCGTGAATGGCATGTAGCTCGT

 5051 GlyMetMetLeuAlaGluGlnPhelysGlnlysAlaLeuGlyLeuLeuGlnThrAlaSer
 GGGATGATGCTGGCCGAGCAGTCAAGCAGAAGGCCCTGGGCTCTGAGACCCGGCTCC
 CCCATSTACGAGCCCTCTCAAGCTCTGCTTCGGGAGGGAGCTGGCTGGCCAGG

 5101 ArgGlnAlaGluValIleAlaProAlaValGlnThrAsnTrpGlnLysLeuGluThrPhe
 CCTCAGGGAGGGTIAOGCCCTGCTGTCAGACCAACTGGCAAAACTCGAGACCTTC
 GCAGTCCGTCCTCAAATAGCGGGGAGCACAGGTCTGGTGTGACCGTCTGGAAAG

 5151 TrpAlaLysHisMetTrpAsnPhelleSerGlyIleGlnTyrLeuAlaGlyLeuSerThr
 TGGCGAAGCATATGGGAACTTATCAGTGGGATACAAACTTGGGGCTTGTCACCC
 ACCCGTTGCTATACACCTTGAATAGTCACCTGATGTAACCGGCCCCAACAGTTGC

 5201 LeuProGlyAsnProAlaIleAlaSerLeuMetAlaPheAlaAlaValThrSerPro
 CTGCTCTGTAACCCGGCATGGCTCATGGATGGCTTACACCTGCTGTACCCAGCCCA
 GACGAGGAACTGGGGCGTAAACGAAAGTAACIACCGAAAATGCGACGACAGTGGTGGGT

 5251 LeuThrThrSerGlnThrLeuPheAsnIleLeuGlyGlyTrpValAlaAlaGlnLeu
 CTAAACCACTAGGCCAAACCCCTCTTCAACATATGGGGGGGGGGCTGGCTGCCAGCTC
 GATGGTGATGGTTGGGAGGAGAGTGTATAACCCCCCAGCCACCGAGGGTGGAG

 5301 AlaAlaProGlyAlaAlaThrAlaPheValGlyAlaGlyLeuAlaGlyAlaAlaIleGly
 CTGGGCTTGGCTACTGGCTTGTGGCTGGCTAGCTGGGCCCATGGC

Figure 1 (Sheet 6 of 10)

CGCGGGGCCACGGGATGACCCAAACCCCCGACCGAATCGACCCGGCGTAGCC
 5521 SerValGlyLeuGlyLysValLeuIleAspIleLeuAlaGlyTyrGlyAlaGlyValAla
 AGTGTGGACTGGGAAGGTCCTTAAGACATCTCAGGCTATGGCCGGCGCTCCGC
 TCACAACCTGACCCCTCCAGGASTATCTGTAGGAACGTCCCATAACCCGCCCCGACCG
 (Gly)
 5581 GlyAlaLeuValIlaPheLysIleMetSerGlyGluValProSerThrGluAspLeuVal
 GGAGCCCTTGAGCAATTCAAGATCATGACGTTAGGGTCCCCTCACGGGAGGACCTGGTC
 CCTOGAGAACACCGTAAGTCTAGTACTCCACTCCAGGGAGGTGCCCTCTGGACCAG
 AsnLeuLeuProAlaIleLeuSerProGlyAlaLeuValValGlyValValCysAlaAla
 5641 AAATCTACTGCCGCATCTCGCCGGAGCTCTCGTAGTGGGCTGGTCCTGGCAGCA
 TTAGAAGACGGGGCTTAGGAGAGCGGCCCTCGGGAGCATAGCCGACCCAGACAGTGT
 IleLeuArgArgHisValGlyProGlyGluGlyAlaValGlnIrpMetAsnArgLeuIle
 5701 ATACTGCGCGGCACGTTGGCCCGGGCGAGGGGAGTGCAGTGGATGAACCGGCTGATA
 TATGACCCGGCCGCTGCAACCGGCCCTCCCTCCCGCTCACGTCACTACTTGGCCCACTAT
 AlaAspAlaSerArgGlyAsnHisValSerProThrHistYrValProGluSerAspAla
 5761 GCGCTCGCTCCCCGGGAAACATTTCCCCAACGCACTACGTGCCCCAGAGCGATCCA
 CGGAAGCGGAGGGCCCCCTGGTACAAAGGGGTGCTGATGACGGCTCTGGCTAGT
 (HisCys)
 5821 AlaAlaArgValThrAlaIleLeuSerSerIleThrValThrSlnLeuLeuArgArgLeu
 GCTGGCCCGCTCACTGCCATACTCAGCCTCACTGTAACCCAGCTCTGAGGGACTG
 CGACCGGGCCAGTGACGGTATGACTGGTGGAGTGAATGGCTGAGGACTCCGCTGAC
 HisGlaTrpIleSerSerGluCysThrThrProCysSerGlySerTrpLeuArgAspIle
 5881 CACCAATGGATAAGCTGGGACTGTACCACTCCATGCTCCGGTCTGGCTAAGGGACATC
 GTGGTACCTTAITCGAGCCTCACATGTTGAGGTACGAGGCCAAGGACCGATTCCCTGAG
 TrpAspTrpIleCysGluValLeuSerAspPheLysThrTrpLeuLysAlaLysLeuMet
 5941 TGGGACTGGATATGGAGGTGTGAGCAGTTAACCTGGCTAAAGCTAACGTCATG
 ACCCTGACCTTAACGGCTCCACAACCTCGCTGAAATCTGGACCGATTTCGATTCGAGTAC
 ProGlnLeuProGlyIleProPheValSerCysGlnArgGlyTyrLysGlyValTrpArg
 6001 CCACAGCTGGCTGGATCCCCTTTGTTGCTCTGCCAGCGCGGTAATAAGGGGCTCTGGCA
 GCTGCGACGGACCTCTGGGAACACAGGACGGTCCGCCATATTCCCCAGACCGCT
 (Val)
 6061 GlyAspGlyIleMetHisThrArgCysHisCysGlyAlaGlnIleThrGlyHisValLys
 GTGGACGCCATCATGCACACTCGCTGGACTGTTGAGGCTGAGATCACTGGACATGTCATA
 CACCTGGCTACTACGGTGTGAGGCCAGGTGACACCTGACTCTGACCTGACAGTT
 AsnGlyThrMetArgIleValGlyPheArgThrCysArgAsnMetTrpSerGlyThrPhe
 6111 AACGGGACGATGAGGATCTCGGTCTCTAGGACCTGGAGAACATGTTGGAGTGGGACCTTC
 TTGCCCCCTGCACTCTGAGCAGGCCAGGATCTGGACGTCCTGACACCTCACCTGGAAAG
 ProIleAsnAlaTyrThrThrGlyProCysThrProLeuProAlaProAsnTyrThrPhe
 6181 CCCATTAAATGCCATACACCAAGGGCCCTGTAACCCCCCTGCCCTGGCCGAACTACACCTTC
 GGGTAAATTACGGGAGTGTGCTCCCCGGGACATGGGGGAGGACCCGGCTTGATGTGCAAG
 AlaLeuTrpArgValSerAlaGluGluTyrValGluIleArgGlnValGlyAspPheHis
 6241 GGGCTATGGAGGGTGTGAGCAGAGGATATGCTGGAGATAAGCCAGGTGGGGACTTCCAC
 CGCGATACTCCACAGACGCTCTCTTAAACACTCTTAACTCCGTCACCCCTGAGGTS
 TyrValThrGlyMetThrThrAspAsnLeuLysCysPheCysGlnValProSerProGlu
 6301 AACCTGACGGGTATGACTGACAAATCTCAAATGCCCCGAGCAGGTCCCCTGCCCCAA
 ATGCACTGCCCATACTGATGACTGTAGACTTACGAGTTACGGGACGGTCCAGGGTAGCGGGCTT
 PhePheThrGluLeuAspGlyValArgLeuLysArgPheAlaProPheCysLysProLeu
 6361 TTTTCACAGAATTGGACCGGGTGCCTTACATAGGTTTGCAGCCCCCTGCAAGCCCTTC
 AAAAGTGTCTAACCTGCCACGGGATGCTATCCAAACGCGGGGGGAGGTTCGGGAAC
 LeuArgGluGluValSerPheArgValGlyLeuHisGluTyrProValGlySerGlnLeu

Figure 1 (Sheet 7 of 10)

6421 CTGGGGAGGAGGTATCATCAGAAGTAGGACTCCACGAATACCCGGTAGGGTGGCAATIA
 GACGCCCTCCATAGTAACTCATCCAGGGTCTTAAGGGCATCCCACCGTTAAT
 6481 ProCysGluProGluProAspValAlaValleuThrSerMetLeuThrAspProSerHis
 CCTTGGAGCCCCAACCGGACCTGGCCCTGCTACGTCCATGCTCACTGAACTCCCTCAI
 GGAACCCCTCGGGCTCGCCCTCACCGGCACAACTCAGGGTACCGAGTGACTACGGAGGGTA
 6541 IleThrAlaGluAlaAlaGlyArgArcLeuAlaArgGlySerProProSerValAlaSer
 ATAACAGCAGAGGGCCCGGCGGCGAGGTGGCGAGGGATCACCCCCCTGTGGCCAGC
 TATITCGCTCTCGCCGCCCGCTTCAACCGCTCCCTAGTGGGGGAGXACACCCGTCG
 6601 SerSerAlaSerGlnLeuSerAlaProSerLeuIleGlySerAlaThrCysThrAlaAsnHisAsp
 TCTCGGCTAGCCAGCTATCCGCTCCATCTCTCAAGGCAACTTCGACCCGCTAACCATGAC
 ACCAGCCGATCGGTGCACTAGGGAGGGTACAGAGTTCGGTGAACGTGGCGATTGGIACTG
 6661 SerProAspAlaGluLeuIleGluAlaAspLeuLeuTrpArgGlnGluMetGlyGlyAsn
 TCCCCTGATGCTGAGCTCATAGGSCCAACCTCCATGGAGGCAGGAGATGGCCGAAAC
 AGGGGACTACGACTCGACTATCTCCGGTGGAGGATACTCCGTCTCTACCCGCGTTC
 6721 IleThrArgValGluSerIleAsnLysValValIleLeuAspSerPheAspProLeuVal
 ATCACCCAGGGTCTGAGTCAGAAAACAAAGTGGTGATTCGGACCTCCCTCGATCGCCTIG
 TAGTGGTCCCAAATCTAGTCCTTGTGTTCAACCCTAAAGACCTGAGGAAGCTAGGCAACAC
 6781 AlaGluGluAspGluArgGluIleSerValPraAlaGluIleLeuArgLysSerArgArg
 GCGGAGGAGGAGCGAGGGGAGATCTCCGTACCCGCAAGAAATCTTCGGAGTCCTGGAGA
 CGCTTCCCTCTGCTCGCCCTCTAGAGGCATGGCGTCTTGGACCCCTTCAGAGCCCT
 PheAlaGluAlaLeuProValTrpAlaArgProAspTyrAspProProLeuValGluThr
 6841 TTGGCCCAAGCCCTGGCCCGGGCCGACTATAACCCCCCGTAGTGGAGAGC
 AACGGGGTCCGGGAAGGGCAAAACCCGGCCGCGCTGATACTGGGGGGGATCACCTTCG
 6901 TrpLysProAspTyrGluProProValValHisGlyCysProLeuProProProLys
 TGGAAAAGCCCGACTACGACCACCTGGTCCATGGCTGTCCCTTCCACCTCCAAAG
 ACCTTTTGGGCTGATGCTGGTGGACKCAGTACCGCAGGGCAAGCTGGAGGTTTC
 6961 SerProProValProProProArgLysLysArgThrValValLeuThrGluSerThrLeu
 TCCCCCTCTGGCTCCGGCTCCGAAGAACGGGACGGCTCTCCSCCTGCCACCAAGGAGT
 AGGGGAGGACACGGAGGGGGAGCCTCTCCSCCTGCCACCAAGGAGTACTTGGGAT
 (Ser)
 7021 SerThrAlaIleAlaGluLeuAlaThrArgSerPheGlySerSerSerThrSerGlyIle
 TCTACTGGCTGGCCGAGCTGGCCACCAGAACCTTGGCAGCTCCCAACTTCGGCAT
 AGATGACCGAACCGGCTCGAGCGGTGGCTCTCGAAACCGTGGAGGAGTTGAAGGCCAA
 ThreGlyAspAsnThrThrSerSerGluProAlaProSerGlyCysProProAspSer
 7081 AGGGGCGACAATACGACAACTCCCTCAGGCCSCTCTCTGCTGCCCTCCGACTCC
 TGCCCCGCTTAAGCTCTGTAGGAGACTCGGCCGGGGAGACCGGAGGGGGCTGAGG
 (PheAla)
 AspAlaGluSerTyrSerSerMetProProLeuGluGlyGluProGlyAspProAspLeu
 7141 GACGGCTGACTCTCTATCCCTCATGCCCCCTGGAGGGGGAGCTGGGATCCGGATCTT
 CTGGGACTCAGGAAAGGGGTACCGGAACTCCCTCGGACCCCTAGGCCTAGGGCTAGAA
 SerAspGlySerTrpSerThrValSerSerGluAlaAsnAlaGluAspValValCysCys
 7201 AGCGACGGGTATGGTCAACCGCTCAGTAGTGGAGGCCAACCGGGAGGATGTCGTTGCTGC
 TGGCTGCCAGTACCAAGCTCCAGTCATCACTCCGGTGGCCCTCTACAGCACACGACG
 SerMetSerTyrSerTrpThrGlyAlaLeuValThrProCysAlaAlaGluGluGlyLys
 7261 TCAAGTGCTACTCTGGACACGGCACTCGTCAACCCCTGCGCCGGGAAGAACAGAAA
 AGTTACAGAACCTGCTCGGGTGGAGCAGTGGGGCACGGGGCCCTTGTCT
 LeuProIleAsnAlaLeuSerAsnSerLeuLeuArgHisAsnLeuValTyrSerThr
 7321 CTGGCCCATCATGCACTAGCAACTCGTGTGCTACGTCACCCAAATTGGTGTATTCCAC
 GACGGGTAGTTACGTGATTCGCTGAGCAGGATGCACTGAGTGGTGTAAACCATAGGTGG
 ThrSerArgSerAlaCysGlnArgGlnLysLysValThrPheAspArgLeuGlnValLeu

Figure 1 (Sheet 8 of 10)

391 ACCCTCACGGCAGTGCTTCCAAAGGCAGAAGAACATGCACTTGACAGACTGCAAGTTGCG
 TCGAGTGGCTCACGAAACGGTTTCCGTCTTCAGCTGAAACTGTCGAGCTTCAGAC
 AspSerHisTyrGlnAspValLeuLysGluValAlaAlaSerLysValLysAla
 441 GACAGCCATTACCAAGGACGTAACCTCAAGGAGGTTAACGCAGCGCGTCAAAAGTGAAAGGCT
 CCTCGGCTATGGTCCTGCAAGTTCCTCCATTTCCTCCCCACTTTCACTGCCA
 (Phe)
 AsnLeuSerValGluGluAlaCysSerLeuThrProProHisSerAlaLysSerLys
 501 AACCTGCTATCCGTAGAGGAACCTTGCAAGCTGACGCCACACTCAGCCAAATCCAAAG
 TCGAGCAAGCTGCGCTCTCCATGCGACCTGCGGGGGTGTGAGTCGGTTAGCTT
 PheGlyTyrGlyAlaLysAspValArgCysH₆AlaArgLysAlaValThrHisIleAsn
 561 TTGGCTATGGCCAAAAGACGTCGCTTCCATCCACAACCCCTAACCCACATCAC
 AACCCATACCCGTTTCTGAGGCAACGGTAACGGCTTTCGGCATGGGTTAGTTG
 SerValTrpLysAspLeuLeuGluAspAsnValThrProIleAspThrThrIleMetAla
 621 TCCGTCGAAAGACCTCTGGAAAGACAATGTAACCCAATAGACACTACCATCATCGCT
 AGGCACACCTTCTGGAAAGACCTCTGGTACATGTTGTTATCTGTGATGCTAGTACCGA
 LysAsnGluValPheCysValGlnProGluLysGlyGlyArgLysProAlaArgLeuIle
 681 AAGAACGAGGTTTCTGGCTTCAGCTGAGAAGGGGGTCGTAAGCCACCTGCTCAIC
 TTCTGCTCCAAAAGACGCAAGTCGGACTCTCCCCCAGCATTGGTCGAGCAGACTAG
 ValPheProAspLeuGlyValArgValCysGluLysMetAlaLeuTyrAspValValThr
 741 GTTTCGCCCCATCTGGCGCTGGCAAAGATGGCTTGTACGACGTTGGTACA
 CACAGGGCTAGACCCGACGGCACACGCTTTCTACCGAACATCTGCCACCAATGT
 LysLeuProLeuAlaValMetGlySerSerTyrGlyPheGlnTyrSerProGlyGlnArg
 7801 AAGCTCCCCCTGGCCGCTGATGGCAACCTCTACGGATCCAAACTACTCACCAAGGACAGGG
 TCGAGGGSAACGGCACTACCCCTTGAGGATGCTTAAGGTATGAGTCGGCTCTGCC
 ValGluPheLeuValGlnAlaTrpLysSerLysTyrProMetGlyPheSerTyrAsp
 7861 GTTGAAATCCCTCGTCAAGCGTGGAAATCCAAGAAAACCCATGGGGTCTCGTATGAT
 CAACTTAAGGAGCACGTPCGCACCTCAGGTTTCTGGGTTACCCCAGAGCAACTA
 ThrArgCysPheAspSerThrValThrGluSerAspIleArgThrGluGluAlaIleTyr
 7921 ACCCGCTGTTGACICCACAGTCACTGAGAGGACATCGTACGGAGGAGCAATCTAC
 TGGCGACCAACTGAGGTGTAGTCAGTCAGCTCGCTGAGCATGCCCTCCGTTAGATC
 GlnCysCysAspLeuAspProGlnAlaArgValAlaIleLysSerLeuThrGluArgLeu
 7981 CAAATGTTGACCTCGACCCCCCAGCGCGCTGGCCATCAAGTCCTCACCGAGAGCTT
 GTTACAACACTGGAGCTGGGTTCTGGGCGCACCGTAGTCAGGGAGTGGCTCTCGAA
 (Gly)
 TyrValGlyGlyProLeuThrAsnSerArgGlyGluAsnCysGlyTyrArgArgCysArg
 8041 TATGTTGGGGCCCTTACCAATTCAAGGGGGAGAACCTGCGGCTATCCAGGTGCGC
 ATACAAACCCCCGGAGAAATGTTAAGTCCCCTCTGAGCGCCGATAGCGTCCACGGCG
 AlaSerGlyValLeuThrThrSerCysGlyAspThrLeuThrCysTyrIleLysAlaArg
 8101 GDEAGCGGCGTACTGACAACCTGCTGCTACACCTCTGGTACATCAAGGGCCCG
 CGCTCGCCGATGACTTTGATGACACCCATTGGGAGTGAACCAATGTTCCGGGCC
 AlaAlaCysArgAlaAlaGlyLeuGlnAspCysThrMetLeuValCysGlyAspAspLeu
 8161 GCAGCCCTGTCAGCCGCGAGGCTCCAGGACTGCAACATGCTGTTGTCGACGACTTA
 CGTCGGACAGCTCGGCCCTCCAGGCTCCAGCTGACCTGCTACACGACACACCCCTGCTGAAT
 ValValIleCysGluSerAlaGlyValGlnGluAspAlaAlaSerLeuArgAlaPheThr
 8221 GTCGTTATCTGIGAAAGCGGGGGTTCAGGAGGACGCCGGCGCTGAGAGSCCTCAAG
 CAGCAATAGACACTTCTGGCCCTCCAGGCTCTGCGCCCTCGGACTCTGGAAAGTCC
 GluAlaMetThrArgTyrSerAlaProProGlyAspProProGlnProGluTyrAspLeu
 8281 GAGGCATGACCAGGTACTCGCCGCCCCCTGGGACCCCCCAACCGAAATACGACTTG
 CTCCGATACTGGTCCATGAGGGGGGGGGACCCCTGGGGGTTGGCTTAAGCTGAAAC
 GluLeuIleThrSerCysSerSerAsnValSerValAlaHisAspGlyAlaGlyLysArg

Figure 1 (Sheet 9 of 10)

8341 CAGCTCATAACATCAGCTCCACGGTGTAGTCGCCCACGACGGGCTGGAAAGAGC
 CTCGACTATTGAGTAGTACGGAGGGAGTTGCACAGTCAGCGGGTGCTGCCGACCTTCCTCC

 8401 Val Tyr Tyr Leu Thr Arg Asp Pro Thr Thr Pro Leu Ala Arg Ala Ala Trp Glu Thr Ala
 GTC TAC TAC CT CAC CC GT GAC CCT AC AAC CC CC CT CG CG AG AG CT CG CT GG AG AC AG CA
 CG AT G AT GG AG TG GG C ACT GG AT GT TG GGG G AG CG CT CG AC CG AC CC CT CT G CG

 8461 Arg His Thr Pro Val Asn Ser Trp Leu Gly Asn Ile Ile Met Phe Ala Pro Thr Leu Trp
 AG AC AC ACT CC CAG TCA AT TC C T G G C T A G G C A A C T A A T C A T G T T G C C C C A C A C T I G I G G
 T C T G I G T G A G G T C A G T T A A G G A C C G A T C C G T G T A T T A G T A C A A A C G G G G T G A C A C C

 8521 Ala Arg Met Ile Leu Met Thr His Phe Phe Ser Val Leu Ile Ala Arg Asp Gln Leu Glu
 GCG AGG AT GATA CT GAT GAC CC AT TT C T T G G C T C T T A T G C C A G G G A C C A G C T T G A A
 CG CT C T C T A T G A C T A C T G G G T A A G A A T C C G A C G G A A T A T C G G T C C T C G T C G A A C T

 8581 Glu Ala Ile Leu Asp Cys Glu Ile Tyr Glu Ala Cys Tyr Ser Ile Glu Pro Leu Asp Leu Pro
 CAG G C C T C G A T T G C G A G A T C T A C G G G C C T G C T A C T C C A T G A A C C A C T T G A T C T A C C T
 G T C C G G A G C T A A C G C T C T A G A T G C C C G A C G A T G A G G T A T C T G G T G A A C T A G A T G G A

 8641 Pro Ile Ile Glu Arg Leu His Gly Leu Ser Ala Phe Ser Leu His Ser Tyr Ser Pro Gly
 C C A N T C A T T C A A A G A C T C C A T G G C C T C A G C G C A T T T C A C T C C A C A G T T A C T C T C C A G G T
 G G T T A G T A A G T T T C G A G G T A C C G G A G T C G C G T A A A A G T G A G G T G T C A T G A G A G G T C C A

 8701 Glu Ile Asn Arg Val Ala Ala Cys Leu Arg Lys Leu Gly Val Pro Pro Leu Arg Ala Trp
 G A A A I T T A A T A G G G T G C C C G C A T G C C T C A G A A A C T T G G G T A C C G C C T T G C G A G C T T G G
 C T T A A T T A T C C A C C G G C G T A C G G A G T C T T G A A C C C A T G G C G G A A C G C T C G A A C C

 8761 Gly
 Arg His Arg Ala Arg Ser Val Arg Ala Arg Leu Leu Ile Ala Arg Gly Gly Arg Ala Ala Ile
 AG AC AC C G G G C C C G G A G C T C C C G C T A G G C T T C T G G C C A G A G G G A G G C A G G G T C G C C A T A
 T C T G T G G C C C C C G G C T C G C A G G C G C G A T C C G A A G A C C G G T C C T C C G T C C C G A C G G T A T

 8821 Cys Gly Lys Tyr Leu Phe Asn Trp Ala Val Arg Thr Lys Leu Lys Leu Thr Pro Ile Ala
 T G T G G C A A G T A C C T C T C A A C T G G G C A G T A A G A A C A A G C T C A A A C T C A C T C C A A T A G G G
 A C A C C G T T C A T G G A G A A G T T G A C C C G T C A T T C T G T T C G A T T G A G T G A G G T T A T C C C

 8881 Ala Ala Gly Gln Leu Asp Leu Ser Gly Trp Phe Thr Ala Gly Tyr Ser Gly Gly Asp Ile
 G C C G T G G C C A G C T G G A C T T G T C C G C T G G C T A C G G C T G G C T A C A G G C G G G A G A C A T T
 C G G C A C C G G T C G A C T G A A C A G G C C G A C C A A G T G C C G A C C G A T G T C G C C C C T C T G T A A

 (Pro)
 8941 Tyr His Ser Val Ser His Ala Arg Pro Arg Trp Ile Trp Phe Cys Leu Leu Leu Leu Ala
 T A T C A C A G G C T G T C T C A T G C C C G C C C G C T G G A T C T G G T T T G C T A C T C C T G C T T G C T
 A T A G T G T C G C A C A G A G T A C G G G C C G G G G C G A C T A G A C C A A A C G G A T G A G G A C G A A C G A

 9001 Ala Glu Val Gly Ile Tyr Leu Leu Pro Asn Arg OP
 G C A G G G G T A G G C A T C T A C C T C C C C A C C G A T G A A G G T T G G G G T A A A C A C T C C G G C C T
 C G T C C C C A T C C G T A G A T G G A G G A G G G G T T G G C T A C T T C C A A C C C A T T T G T G A G G C C G G A

Figure 1
Sheet 10 of 10

EP 0 450 931 A1



Figure 2



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number

EP 91 30 2910

DOCUMENTS CONSIDERED TO BE RELEVANT						
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claims	CLASSIFICATION OF THE APPLICATION (Int. CL.5)			
Y	WO-A-8 904 669 (CHIRON CORP.) * Page 39, lines 8-12; page 49, line 5 - page 50, line 31; page 123, line 29 - page 125, line 22; page 132, line 3 - page 134, line 35; page 171, lines 4-20 *	1-16	G 01 N 33/576 C 07 K 15/00			
Y,D	EP-A-0 318 216 (CHIRON CORP.) * Page 15, line 39 - page 17, line 8; page 18, line 44 - page 19, line 13; page 27, lines 10-22 *	1-16				
A	SCIENCE, vol. 244, 21st April 1989, pages 362-364, Washington, DC, US; G. KUO et al.: "An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis" * Whole article *	1-16				
			TECHNICAL FIELDS SEARCHED (Int. CL.5)			
			G 01 N C 07 K			
<p>The present search report has been drawn up for all claims</p> <table border="1"> <tr> <td>Place of search THE HAGUE</td> <td>Date of completion of the search 02-07-1991</td> <td>Examiner VAN BOHEMEN C.G.</td> </tr> </table>				Place of search THE HAGUE	Date of completion of the search 02-07-1991	Examiner VAN BOHEMEN C.G.
Place of search THE HAGUE	Date of completion of the search 02-07-1991	Examiner VAN BOHEMEN C.G.				
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons A : member of the same patent family, corresponding document				

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.